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This protocol describes the EVRA study and provides information about procedures 
for entering participants. Every care was taken in its drafting, but corrections or 
amendments may be necessary. These will be circulated to investigators in the study. 
Problems relating to this study should be referred, in the first instance, to the Chief 
Investigator.  
This study will adhere to the principles outlined in the NHS Research Governance 
Framework for Health and Social Care (2nd edition). It will be conducted in 
compliance with the protocol, UK Clinical Trials Regulations, the Data Protection Act 
and other regulatory requirements as appropriate.  
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1. INTRODUCTION  
1.1 BACKGROUND  
Chronic leg ulcers are open “sores” on the lower limbs situated between the ankles 
and knees, which fail to heal within 6 weeks. These ulcers represent a source of 
great discomfort and social isolation to patients who often complain of associated 
pain, odour and wound discharge. The time taken for the ulcers to heal means that 
the condition is also particularly frustrating to health carers involved in their 
management in hospital and community settings. The underlying cause of leg 
ulceration in over 70% of cases is lower limb venous dysfunction, sometimes evident 
as varicose veins but often undetectable by visual examination alone1. The 
estimated overall prevalence of active venous ulceration is as high as 1.5 to 1.8 per 
1000 population, increasing to 3.8 per 1000 population in those over 40 years of 
age2 3. As patients with venous ulceration usually suffer episodes of recurrence 
between periods when the ulcer remains healed, the number of patients with a high 
risk of ulceration may actually be 4-5 fold higher4. It should also be noted that with an 
aging and increasingly obese population5, the incidence and prevalence of venous 
ulceration are both likely to increase. Treatment of the condition in the UK produces 
a substantial cost burden estimated at £400-600 million per annum6.  
Venous ulcers are characterised by protracted healing times. Despite some recent 
advances in the management of patients with venous ulcers, 24 week healing rates 
in published randomized trials are around 60-65%7 8, and the true population healing 
rates are likely to be significantly lower. Some patients may never heal and those 
that do heal are at high risk of recurrent ulceration. These poor outcomes are likely 
to be a reflection of the severe underlying venous dysfunction in this patient group, 
although inadequate assessment and suboptimal treatment are also likely to be 
important contributing factors. 
1.1.1 Pathophysiology of venous ulceration 
The venous circulation of the lower limb has two components, the deep and 
superficial systems. Blood normally flows from the superficial to the deep veins and 
is prevented from flowing back down the leg under the influence of gravity by ‘one-
way’ valves along the veins. When these valves become incompetent (leaky), the 
superficial veins usually become dilated and tortuous (varicose) and the resulting 
sustained high venous and capillary pressures lead to skin inflammation and 
ulceration (breakdown of skin). The deep veins also have valves, which may also 
become incompetent, but are not visible on the skin. Duplex ultrasound studies9 10 11 
on patients in leg ulcer clinics suggest that: 
 Around 50% of patients with venous leg ulcers have diseased superficial veins 
alone, with a further 30-40% having a mixture of superficial and deep venous 
disease. Both of these groups of patients benefit from correction of their 
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superficial venous reflux, which has been shown to reduce the risk of ulcer 
recurrence12. 
 A minority (5-10%) of patients with venous ulcers have diseased deep venous 
systems only, and are not amenable to surgical correction. These patients are 
usually treated with compression bandaging alone 
Ulcer healing strategies are based on efforts to reduce this leakage (reflux) of blood 
back down the leg and into the skin, as this is considered the most significant cause 
of high venous pressure in most patients. Longstanding venous hypertension has 
been shown to cause a number of changes to the microcirculation in the lower leg, 
which can contribute to the chronic skin changes or eventual ulceration associated 
with chronic venous disease13. Compression bandaging to the leg (which may need 
to be re-applied 1-4 times per week) counteracts the gravitational force on the blood, 
in effect temporarily replacing the incompetent valves14. Diseased superficial veins 
can be surgically removed (open varicose vein surgery) or ablated using 
endovenous interventions (see below) without harming the overall venous function of 
the leg, theoretically removing a causative factor for recurrence of the ulcer after the 
compression bandaging has ceased. The deep vein defects are not generally 
amenable to surgery. 
1.1.2 Treatment options for superficial venous reflux 
For over a century, the treatment of superficial venous reflux has involved operative 
ligation and surgical stripping of the vein and avulsion of bulging varicose veins15. 
Until recent years, open surgery has been considered the definitive treatment option 
for superficial venous reflux. However, the operation usually requires general 
anaesthesia and patients often suffer discomfort, bruising and significant time off 
work in the post-operative period. Long-term studies have also identified significant 
complications of open surgery including nerve damage and recurrence of varicose 
veins, seen in over 60% of patients at 11 years in one randomized study16.  
In response to this high complication rate and a growing patient desire for less 
invasive treatments, a range of novel, minimally invasive endovenous treatment 
options have been developed and have gained in popularity over the last decade. 
Interventions such as ultrasound guided foam sclerotherapy (UGFS)17, endovenous 
laser (EVLA)18 or radiofrequency ablation (RFA)19 can be performed using local 
anaesthesia in an outpatient setting. These treatments involve cannulation of the 
vein to be treated (usually under ultrasound guidance) and obliteration of the venous 
channel by either chemical ablation (using foam sclerosant), or thermal ablation 
(using a laser or radiofrequency fibre). Numerous randomized studies have 
demonstrated that endovenous modalities are, at worst, comparable to open surgery 
in terms of recurrence (and likely to be better), but clearly superior in terms of pain, 
bruising and other early complications20-22. Each of the different endovenous 
modalities has advantages and potential disadvantages, although all are less 
invasive than traditional open surgery. This is of particular relevance to patients with 
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chronic venous ulceration, who are often elderly, have extensive co-morbidities and 
may be reluctant to undergo surgical procedures involving general anaesthesia. 
Endovenous techniques can also be performed without discontinuing anti-
coagulation therapy, which is increasingly prescribed in this patient population. 
1.1.3 Summary of current research 
The most significant study of superficial venous intervention in patients with venous 
ulceration is the ESCHAR study (Barwell, Poskitt; Lancet 2004 & Gohel, Poskitt; 
BMJ 2007)7 12. The study aimed to evaluate the role of traditional superficial venous 
surgery in reducing ulcer recurrence in patients with open or recently healed venous 
ulcers. Following prospective observational studies to inform power calculations, a 
total of 500 patients were randomized to compression therapy alone or compression 
with open surgery for superficial venous reflux. The group randomized to surgical 
treatment had significantly lower venous ulcer recurrence rates at 4 years (Figure 1).  
Analysis stratified by pattern of venous reflux demonstrated that this clinical benefit 
was present for patients with isolated superficial venous reflux and patients with 
superficial and segmental deep reflux. This clearly indicated that the majority of 
patients with chronic venous ulceration could benefit from superficial venous 
intervention. As a result, the current optimal management of patients with venous 
ulceration includes the treatment of refluxing superficial veins to reduce the risk of 
ulcer recurrence23.  
Analysis of ulcer healing within the ESCHAR trial demonstrated that there was no 
significant improvement in ulcer healing rates for the group randomized to 
compression plus surgery (Figure 2). This finding has led many to conclude that 
treatment of venous reflux does not have a role in patients with open ulcers.  
 
 
 
 
 
 
 
 
 
However, the ESCHAR study was designed and powered to assess ulcer recurrence 
rather than healing, and the statistical power of this trial was further weakened by a 
high cross-over rate, as around a quarter of patients randomized to surgery 
subsequently refused to have an operation. This highlights the need for a minimally 
invasive superficial venous treatment modality in this patient group. In addition, the 
Figure 1. ESCHAR trial – ulcer 
recurrence 
Figure 2. ESCHAR trial – ulcer 
healing 
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median time to treatment within the study was around 2 months, by which time 
smaller ulcers may have already healed with compression bandaging, and, in many 
cases, the surgical procedures used were suboptimal when judged by current 
standards. Consequently, it is plausible that the benefits of treating superficial 
venous reflux were underestimated in this study, particularly for the assessment of 
ulcer healing.  
In a smaller Dutch randomized trial, 170 patients (200 legs) were randomized to 
compression alone or compression with surgical treatment of superficial reflux 
(including subfascial endoscopic perforator surgery – SEPS)8. Although results did 
not reach statistical significance, there was a clear trend towards improved ulcer 
healing rates and greater ulcer free time in the group randomized to surgery.  
Despite the widespread acceptance of endovenous modalities, few prospective 
studies have been published reporting outcomes after endovenous treatment in 
patients with leg ulcers. In a prospective study of 186 patients with leg ulceration 
treated with UGFS, the ulcer healing rate was over 70% and the patient acceptability 
of treatment was excellent (Poskitt et al)24. In a further study of foam sclerotherapy in 
130 patients, a healing rate of 82% was achieved (Bradbury et al)25. Whilst these 
small non-randomized studies lend support to our hypothesis that early intervention 
to correct superficial venous reflux will promote ulcer healing, a large randomized 
trial is required to provide reliable evidence and thus change practice. 
 
1.2 RATIONALE FOR CURRENT STUDY  
Whilst the management of patients with venous ulcers has evolved in recent years 
and ulcer healing and recurrence rates have shown some improvement, we believe 
that there is a strong argument in favour of this study at this time for the following 
reasons: 
 The prevalence of venous ulceration is likely to increase, particularly with an 
aging and increasingly obese population. In view of the significant financial and 
psychosocial costs of venous ulceration, it is imperative that the optimal 
treatment strategies are identified.  
 Despite numerous studies of topical ulcer treatments, the only treatment shown 
to improve venous ulcer healing is compression bandaging. Compression 
supports the venous circulation, but is poorly tolerated by some patients and 
does not address the underlying problem of venous reflux. The intervention in this 
proposal involves treating the underlying anatomical venous disorder using 
effective, minimally invasive endovenous interventions and offers a logical, 
deliverable and long-term approach to reducing venous hypertension.   
 The treatment of superficial venous reflux has been transformed in recent years 
through the widespread use of minimally invasive, endovenous interventions, 
which patients find more acceptable than traditional open surgery. 
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 Ablation of superficial reflux should be considered in all patients with leg ulcers 
and superficial venous reflux, but if early intervention is associated with moderate 
improvements in ulcer healing compared to deferred intervention (i.e. post-
healing), significant cost savings could be realised.  
 Patients find venous leg ulcers painful, distressing and a significant inhibition to 
normal, independent life. Interventions to reduce the time to healing could reduce 
patient distress and significantly improve quality of life.  
Therefore, we believe that there is a cogent argument for conducting this trial at this 
time. Non-randomized studies suggest that outcomes may be improved by treating 
underlying superficial reflux using the latest technologies, but there is no robust 
evidence to support early intervention. The research team has a strong track record 
in relevant research areas and includes clinicians and researchers who successfully 
completed the landmark clinical trial on which this proposal is based (ESCHAR trial), 
and numerous other high impact clinical trials evaluating treatments in venous 
ulceration. 
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2. OBJECTIVES 
2.1 PRIMARY OBJECTIVE 
What is the clinical and cost effectiveness of early endovenous treatment of 
superficial venous reflux in addition to standard care compared to standard care 
alone in patients with chronic venous ulceration? 
 
2.2 SECONDARY OBJECTIVES 
To investigate: 
 The ulcer free time to 1 year 
 The technical success of endovenous interventions 
  
EVRA Protocol Version 1.0  Dated: 19/06/2013 
Approved by The NRES Committee South West - Central Bristol REC on 15/08/2013 
9 
 
3. PARTICIPANT ENTRY  
3.1 PRE-REGISTRATION EVALUATIONS  
Prior to commencing, information will be disseminated to GP practices in each 
recruiting region and meetings will be arranged with key community nursing staff and 
at leg ulcer clinics to promote the trial. Patients would be referred to secondary care 
as part of the standard care pathway. 
At the referral visit patients will be given an appropriate time period to consider 
participation (at least 24 hours). Written consent will be obtained from those patients 
who agree to participate and randomization will be performed using the online 
service. For patients randomized to endovenous ablation of superficial venous reflux, 
a date for intervention will be booked as soon as possible (i.e. within 2 weeks). At 
each recruiting centre, an online log of all screened patients will be kept using the 
InForm system. Basic demographic data and reasons for non-eligibility will be 
recorded. Whilst participant baseline characteristics may vary slightly across 
recruiting sites, randomized treatment allocation will allow reliable assessment of the 
effects of early versus delayed endovenous ablation in ulcer healing. 
3.2 INCLUSION CRITERIA  
 Current leg ulceration of greater than 6 weeks, but less than 6 months duration 
 Able to give informed consent to participate in the study after reading the patient 
information documentation 
 Patient age > 18 years 
 Ankle Brachial Pressure Index (ABPI) ≥ 0.8 
 Superficial venous disease on colour duplex assessment deemed to be 
significant enough to warrant ablation by the treating clinician (either primary or 
recurrent venous reflux) 
Patients who cannot speak / understand English will be eligible for inclusion and 
informed consent will be obtained with assistance from translation services as per 
standard clinical practice. In view of the lack of cross-cultural validation for quality of 
life tools, only healing outcome data will be collected. 
3.3 EXCLUSION CRITERIA  
 Presence of deep venous occlusive disease or other conditions precluding 
superficial venous intervention (at the discretion of local research team) 
 Patients who are unable to tolerate any multilayer compression bandaging will be 
excluded. However, concordance with compression therapy can be variable for 
patients at different times. Patients who are generally compliant with compression, 
but unable to tolerate the bandages for short periods will still be eligible to 
inclusion. A period of non-compliance with compression bandages will not be 
considered a protocol violation, but a normal variation within the spectrum of 
‘standard therapy’.  
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 Inability of the patient to receive prompt endovenous intervention by recruiting 
centre 
 Pregnancy (female participants of reproductive age will be eligible for inclusion in 
the study, subject to a negative pregnancy test prior to randomisation)  
 Leg ulcer of non-venous aetiology (as assessed by responsible clinician) 
 If patient is deemed to require skin grafting they cannot be included 
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4. STUDY DESIGN  
The EVRA ulcer trial is a pragmatic; multicentre randomized clinical trial with 
participants randomized 1:1 to either: 
1. ‘Standard’ therapy consisting of multilayer elastic compression bandaging with 
deferred treatment of superficial reflux (usually once the ulcer has healed) 
2. Early endovenous treatment of superficial venous reflux (within 2 weeks) in 
addition to standard therapy 
The study design is summarised in Figure 3 below.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
                                                       * Assessments of ulcer healing will be on going throughout the study 
fo                                                 follow-up period and will be performed by community nursing teams 
a                                                  and research staff (at least every month) 
          **Once the research team has been informed by the patient that the 
ulcer has healed. Can occur any time during the 12 months. 
POTENTIAL PARTICIPANTS 
SCREENED FOR ELIGIBILITY 
BASELINE VISIT 
Consent & Randomisation 
Clinical Assessment 
Photo/Tracing of Ulcer 
Quality of life questionnaire 
6 WEEKS 
Quality of life questionnaire 
Assessments of ulcer healing * 
Colour duplex scanning (EVRA group only) 
Multilayer compression alone 
 
Multilayer compression + EVRA 
 
ENDOVENOUS ABLATION OF 
SUPERFICIAL REFLUX   
(within 2 weeks) 
 
ENDOVENOUS ABLATION 
OF SUPERFICIAL REFLUX 
(once ulcer healed) 
 
6 MONTHS 
Self completed quality of life questionnaire 
Assessments of ulcer healing * 
12 MONTHS 
Self completed quality of life questionnaire 
Assessments of ulcer healing * 
VERIFICATION VISIT 
4 weekly photos of the 
ulcer** 
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4.1 PATIENT RANDOMIZATION 
The normal clinical team will make initial contact with potentially eligible patients at 
the referral visit.  
Those who consent will be registered on the InForm ITM (Integrated Trial 
Management) System, a web-based data entry system, which is maintained by ICTU, 
and their eligibility for the study confirmed.  A randomization list will be loaded onto 
the InForm system for each centre (as stratification will be by centre) before 
recruitment commences, having been prepared in advance by a statistician who is 
independent of the study. Each potential participant, if confirmed to be eligible, will 
be assigned the next available entry in the appropriate randomization list (i.e. without 
foreknowledge). Thereafter, treatment allocation will not be blinded (with the 
exception of assessment of ulcer healing – see 4.3.1). For patients with bilateral 
venous ulceration, the worst leg (according to the patient) will be designated the 
‘reference leg’. Interventions may be performed on both legs, if deemed appropriate 
by the responsible clinician. 
4.2 STUDY SETTING 
Eligible patients with chronic venous ulcers will be recruited from the following 
centres: 
1. Imperial College Healthcare NHS Trust (PI: Professor AH Davies) 
2. Cambridge University Hospitals NHS Foundation Trust (PI: Mr MS Gohel) 
3. Gloucestershire Hospitals NHS Foundation Trust (PI: Mr KR Poskitt) 
4. West Midlands Vascular Research Collaborative (Heart of England NHS Trust; 
University Hospital Birmingham NHS Trust; City and Sandwell NHS Trust; 
Russell’s Hall Hospital NHS Trust, Dudley; and New Cross Hospital NHS Trust, 
Wolverhampton) (PI: Professor A Bradbury) 
5. North West London Hospitals NHS Trust (PI: Miss SR Renton) 
6. Worcestershire Acute Hospitals NHS Trust (PI: Mr I Nyamekye) 
 
4.3 STUDY OUTCOME MEASURES  
4.3.1 Primary outcome measure 
The primary outcome measure will be time to ulcer healing (from date of 
randomization to date of healing). For the purposes of this study, ulcer healing is 
defined as complete re-epithelialisation of all ulceration on the randomized leg. 
Community or hospital healthcare staff, depending on the local model of care, will 
perform assessment of ulcer healing.  
Data on the status of the reference leg will be collected throughout the study by 
research staff scrutinising community medical / nursing records and contacting the 
patient / community nursing teams by telephone (on a monthly basis at least). 
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If either the community nursing / medical staff or the patient believe that ulcer healing 
(defined as complete re-epithelialisation of the ulcerated leg) has been achieved, 
they will be asked to contact the local research centre immediately. This notification 
of possible ulcer healing will constitute a ‘trigger’ for the research staff at the 
recruiting centre to arrange an urgent verification assessment by a member of the 
healthcare team (within 1 week).  
Verification will be by clinical assessment and digital photography, to be repeated 
weekly for 4 weeks. The digital images will be evaluated by two blinded expert 
assessors in order to ascertain the date of healing, which will be considered the 
primary healing end-point. Disagreements will be resolved through discussion with 
involvement of a third blinded expert reviewer if necessary. This approach will be 
applied to patients in both treatment arms and is consistent with the methods utilized 
in other large HTA funded leg ulcer trials (e.g. VenUS IV). Legs deemed to have an 
open ulcer on clinical assessment would continue within the study. If healing is 
confirmed by clinical and blinded photograph assessments at the first verification 
visit, the date of healing notification (by patient or community nurse) will be taken as 
the date of ulcer healing. 
4.3.2 Secondary outcome measures 
A number of secondary outcome measures will be evaluated in the EVRA study: 
1. Ulcer Healing Rate: Healing rate will be evaluated in addition to time to ulcer 
healing to allow comparison with other published studies.  
2. Ulcer Free Time: Will be calculated up to 1 year for each study arm. This will 
allow a very practical and easily understood assessment of the clinical difference 
between the 2 arms of the study. This will also allow comparison with other 
studies that have reported this outcome. In order to facilitate accurate calculation 
of ulcer free time, clinical follow up will be continued after ulcer healing up to 1 
year after randomisation. 
3. Quality Of Life (QoL): Disease specific (AVVQ) and generic (EQ5D & SF36) 
quality of life assessments will be compared at 6 weeks post randomisation, 6 
months and 12 months. The 6-week questionnaire will be given to the patient at 
the follow-up appointment, whereas other QoL questionnaires will be sent to the 
patient. AVVQ is the most widely utilised disease specific QoL tool in venous 
disease and has been extensively validated. A score out of 100 points is 
calculated, with a higher score indicating more severe QoL impairment. Changes 
in QoL scores will offer a comparison with other studies and, in the standard 
treatment arm, will allow an assessment of the natural history of venous 
ulceration treated with compression.  
4. Health Economic Assessment: Cost items in hospital and community care will be 
recorded for each patient. Standard HRG published tariffs will be used to 
calculate overall costs. A standard tariff will be applied for each bandage change, 
although additional treatments administered for the treatment of symptoms or 
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complications directly related to venous ulceration will be included. Utilities 
(QALYs) will be calculated from generic QoL questionnaire and cost-
effectiveness will be analysed.  
5. Other Markers Of Clinical Success: The Venous Clinical Severity Score (VCSS) 
will be assessed at 6 weeks. In addition, the incidence of complications related to 
the endovenous intervention as well as the presence of residual / recurrent 
varicose veins will also be assessed at 6 weeks.  
 
4.4 DURATION OF FOLLOW-UP 
In the present study, participants will be followed-up until either: 
1. 1 year post-randomization 
2. Patient choice to withdraw from the study. Patients who no longer wish to 
complete quality of life questionnaires will be asked if they would object to the 
use of healing status data (to contribute to the primary outcome) 
3. Death 
In order to allow assessment of ulcer free time to 1 year, patients with healed ulcers 
will be evaluated using telephone follow-up (performed by staff at the recruiting 
centre) on a monthly basis until 1 year. The aim of the telephone follow-up will be to 
confirm that the ulcer remains healed, or in cases of ulcer recurrence, to ascertain 
the date of recurrence and of subsequent healing. More prolonged post-intervention 
follow-up for several years is required to obtain reliable long-term recurrence rates in 
both treatment groups. Accordingly, participants will be asked to consent to long-
term follow-up at the outset, and funding for an extension to EVRA will be sought in 
due course. 
4.5 STUDY DURATION 
The EVRA study will take four years to complete. The overall study timetable is 
summarised in Figure 4. 
 
 
  
Funding 
award 
Month 
12 
Month 
24 
Month 
36 
Month 
48 
Stage 1: Set up 
Stage 2: Recruitment phase  
(after staggered introduction of centres) 
Stage 3: Completion of follow-up 
Stage 4: Write-up 
and close out 
 Figure 4. EVRA study Gantt chart  
EVRA Protocol Version 1.0  Dated: 19/06/2013 
Approved by The NRES Committee South West - Central Bristol REC on 15/08/2013 
15 
 
5. DETAILS OF INTERVENTIONS 
5.1 VARIATIONS IN ENDOVENOUS INTERVENTIONS 
A wide range of endovenous treatment modalities are now available and in 
widespread use for the ablation of superficial venous reflux. These include: 
 Endovenous thermal ablation using laser or radiofrequency 
 Ultrasound guided foam sclerotherapy (UGFS) 
 Other endovenous interventions such as mechanochemical ablation, steam 
ablation and glue 
 Any combination of the above treatments 
In addition to the different modalities in use, the treatment strategy may also vary 
between institutions and between individual clinicians within the same department. 
Variations may occur in: 
 Site of vein cannulation (and therefore the length of vein ablated) 
 Location of treatment (‘office’ or clinic based versus operating theatre) 
 Treatment strategy for sub-ulcer venous plexus (to ablate or not) 
 The treatment of visible varicose veins (no treatment, UGFS or surgical 
avulsion) and the timing of any intervention 
5.2 STANDARDISATION OF INTERVENTIONS IN EVRA STUDY 
With the lack of consensus on a single, optimal endovenous treatment strategy for 
superficial reflux in patients with leg ulceration, perfect standardisation of 
interventions will be impossible. All endovenous interventions should be performed 
as deemed to be ‘optimal’ by the treating clinician for each individual patient, with the 
following stipulations: 
1. The endovenous strategy must include ablation of the main truncal venous 
reflux 
2. Truncal venous reflux should be treated to the lowest point of incompetence, 
where possible 
3. Significant (as deemed by the treating clinician) residual / recurrent superficial 
reflux on the 6 week duplex scan, should be ablated 
4. Patients should continue with multilayer compression immediately after 
treatment 
5.3 STANDARDISATION OF COMPRESSION 
Patients will receive the standard compression used in the individual centres prior to 
ulcer healing following randomisation (this will include four layer bandaging, three 
layer bandaging, European short stretch, stockings). Post healing the patients will be 
given compression hosiery in line with local policy.   
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5.4 FURTHER TREATMENT FOR COMPRESSION ALONE ARM 
Patients randomised to multilayer compression alone can be offered endovenous 
treatment of superficial reflux once healing has been confirmed (see 4.3.1). 
Endovenous ablation should be performed as per standard practice in the treating 
centre and details of this will be recorded. Endovenous intervention may also be 
offered if there is clinical deterioration in the active leg ulcer and it is clinically felt that 
the patient may benefit from early intervention. This will be recorded on the 
electronic case report form. 
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6. ASSESSMENT AND FOLLOW-UP  
6.1  PATIENT IDENTIFICATION 
Patients will be referred to secondary care for evaluation of the management of their 
leg ulcer as part of the standard pathway of care. 
6.2 REFERRAL VISIT 
At the initial visit the patient will be evaluated by clinical assessment and colour 
duplex examination, which is part of the normal investigation of a patient with leg 
ulceration. Dependant on the results of these tests, the patient will be asked if they 
would consider taking part in the trial and approached for consent. The patient will be 
given a minimum of 24 hours to consider the trial and if willing to participate will 
return to the leg ulcer clinic to give consent and undergo a baseline visit.  
6.3 BASELINE VISIT  
Patients will undergo detailed clinical assessment by the research nurse as part of 
the baseline evaluation (see Appendix 1). Recorded assessments will include: 
 Demographic details (age, sex, ethnicity) 
 Pregnancy test for woman of child bearing potential 
 General clinical details (body mass index, ankle brachial pressure index – 
performed within previous 4 weeks, comorbidities, medication history) 
 Ulcer details (duration, progression, previous ulcer history, size of current ulcer – 
using photography and planimetry)  
 Assessment of range of ankle movement 
 Details of venous disease (previous deep vein thrombosis, previous venous 
interventions, pattern of venous reflux on duplex) 
Additional assessments will include: 
 Assessment of Clinical, Etiologic, Anatomic, Pathophysiological (CEAP) score 
 Assessment of venous clinical severity score (VCSS) 
 Disease specific (Aberdeen varicose vein questionnaire – AVVQ) and generic 
(EuroQuol 5D – EQ5D & short form (SF) 36) quality of life assessments  
At this visit, eligible and consenting patients will be randomised into the trial. 
 
6.4 FOLLOW-UP ASSESSMENTS 
Randomized patients will undergo routine leg ulcer care in community or hospital (or 
both) settings, in accordance with the local standard. This will equate to wound 
reviews and dressing changes ranging between once and 4 times per week 
(depending on the ulcer). The exact nature of dressings and date of dressing change 
will be documented by community or hospital healthcare professionals. This will 
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allow an accurate record of the dressing types used and will be collected and verified 
by the research nurse. 
In addition, the following assessments will be conducted: 
6.4.1 6-week clinic visit 
 Clinical assessment 
 In the compression plus early venous reflux ablation group, venous duplex 
scanning will be performed at 6 weeks post-randomization to verify anatomical 
treatment success. Depending on the results of the scan, the decision to perform 
further superficial venous interventions will be left to the discretion of the 
responsible clinical staff. Irrespective of the number and timing of venous 
interventions, all analyses will be performed on intention to treat. 
 Wound tracing and photo 
 Assessments of disease specific and generic quality of life (AVVQ, EQ5D & SF36) 
by means of self completed questionnaire 
6.4.2 Further follow-up 
 Assessments of disease specific and generic quality of life (AVVQ, EQ5D & SF36) 
by means of self completed questionnaire at 6 months and 12 months post-
randomization (sent to the patient). 
 The research team will perform monthly telephone evaluation of the patient and 
access the community notes or telephone the community nurses in order to 
collect and verify the data collected. 
 Once the research team has been informed that the ulcer has healed the patient 
will undergo an urgent verification visit 
6.5 URGENT VERIFICATION VISIT 
 A member of the local research team will perform the four verification visits to 
confirm healing. Photographs will be taken and send to the Trials Unit for 
independent verification.  
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7. STATISTICS AND DATA ANALYSIS 
Data and all appropriate documentation will be stored for a minimum of 10 years 
after the completion of the study, including the follow-up period.  
7.1 SAMPLE SIZE CALCULATION 
The sample size calculation for this study was based on the primary outcome of 
ulcer healing. The ESCHAR trial was a similar randomized study, which published 
the final results in 2007 (see 1.1.3). A total of 500 patients with open or recently 
healed venous ulcers were randomized to standard therapy alone or standard 
therapy plus open surgery for superficial venous reflux. The study was powered and 
designed to evaluate differences in ulcer recurrence (rather than healing). 
Consequently, the median time from randomization to treatment delivery was over 7 
weeks. Nevertheless, the 24-week healing rate in patients randomized to standard 
treatment (compression alone) was approximately 60%. Two recent prospective 
studies evaluating the early treatment of superficial venous reflux suggested that the 
24-week healing rate may be as high as 82%24 25.  
In order to calculate a sample size for this study, we estimate a benefit associated 
with early treatment of around 15%. To identify a difference in 24-week healing rates 
of 15% between the two groups with 90% power will therefore require 208 subjects 
(68 healed leg ulcers) per group (log-rank test).  With 10% dropout the study will 
therefore require 462 subjects (231 in each arm). To incorporate further allowances 
for protocol violations and unexpected dropouts, the target sample size will be 500 
patients. 
 
7.2 PLANNED ANALYSES 
Basic descriptive methods will be used to present the data on study participants, trial 
conduct, clinical outcomes and safety (in total and for each study group separately). 
The primary outcome will be time to complete healing and we will test the hypothesis 
that there is no difference in this between the control and intervention groups using a 
log-rank test (two-tailed, 5% significance level). Kaplan-Meier survival curves will 
also be presented and as a subsidiary analysis we will investigate the effect of study 
centre, participant age, ulcer size and chronicity on time to complete healing using 
Cox regression. To adjust for potential surgeon and centre effects, surgeon and 
centre will be included in the Cox regression analysis as random effects. All analyses 
will be on an intention-to-treat basis. Non-compliance with allocated interventions 
and other protocol violations will be kept to a minimum. Accordingly, per-protocol 
analyses are not envisaged, and the chief emphasis will be on the overall result on 
time to ulcer healing. 
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7.3 HEALTH ECONOMIC ANALYSIS 
The economic evaluation will be based on both a modelling exercise and a patient 
level in-trial analysis. The analysis will be performed from the perspective of the NHS 
and society. The economic model will be developed from the model used for another 
HTA funded project (REACTIV trial)26. The model will assess the relative cost-
effectiveness (assessed in terms of incremental cost per QALY), of the treatment 
strategies. The trial data will inform the model and further data (including that for 
other relevant comparators) will come from the literature and other data sources. 
Use of secondary and primary care patient resource use and EQ-5D responses will 
come from the trial. They will be collected by case note review and questionnaires 
completed at baseline, 6 and 12 months. Unit costs will be based on nationally 
available data and study-specific estimates. QALYs will be estimated using 
responses to the EQ-5D. The results of the economic model will be supplemented by 
an in-trial analysis. The trial analysis will use the estimates of costs and QALYs 
estimated for each trial participant to calculate the incremental cost-effectiveness 
ratios for the 12-month follow-up. The results of the analyses will be presented as 
estimates of mean incremental costs, effects, and, incremental cost per QALY. 
Sensitivity analysis will be conducted for both model and trial based evaluations. The 
results of the base case and sensitivity analyses will be presented as mean 
estimates and as cost-effectiveness acceptability curves (CEACs). 
 
7.4 INTERIM ANALYSES: ROLE OF THE DATA MONITORING 
COMMITTEE 
During the study, interim analyses of all related SAEs and other study outcomes will 
be supplied in strict confidence to the independent Data Monitoring Committee 
(DMC). The DMC will request such analyses at a frequency relevant to the stage of 
the study (typically at 12 monthly intervals with a Chairman’s review every 6 months) 
or in response to emerging data from other trials. Unless advised by the DMC in 
response to clear evidence of benefit or hazard, the Steering Committee, 
collaborators, participants and all study staff (except those who provide the 
confidential analyses to the DMC) will remain blind to the interim results until the end 
of the study. 
In the light of these interim analyses and any other information considered relevant, 
the DMC will advise the Steering Committee if, in their view, the randomized 
comparisons in the study have provided both (i) “proof beyond reasonable doubt” * 
that early correction of superficial venous reflux improves ulcer healing; and (ii) 
evidence that might reasonably be expected to influence materially patient 
management.   
* Appropriate criteria of proof beyond reasonable doubt cannot be specif ied precisely, but a difference of at least 3 standard 
deviations in an interim analysis for healing may be needed before stopping the trial prematurely. Furthermore, this criterion 
has the practical advantage that the exact number of interim analysis w ould be of little importance, so no f ixed schedule is 
proposed. 
EVRA Protocol Version 1.0  Dated: 19/06/2013 
Approved by The NRES Committee South West - Central Bristol REC on 15/08/2013 
21 
 
The DMC would also be expected to advise the Steering Committee if clear evidence 
emerged of an adverse effect on intervention-related SAEs, and if this hazard 
seemed likely to outweigh any potential benefit. 
 
7.5 LOSSES TO FOLLOW-UP AND PROTOCOL VIOLATIONS 
The primary assessment involves intention-to-treat analysis. Therefore, strenuous 
efforts will be made to ensure that only patients willing to undergo either immediate 
or delayed superficial venous ablation and compression bandaging are randomized. 
Monthly reports of protocol violations will be provided by local sites to the trial 
coordinators, who reserve the right to suspend or exclude sites in the event of wilful 
protocol violations. Similarly, efforts will be made to obtain complete follow-up for all 
randomized participants (irrespective of whether or not they underwent allocated 
treatment). For those participants unable or unwilling to attend follow-up 
appointments, home-visits or follow-up by community nurses may be considered. 
We appreciate that a high rate of protocol violations was seen in previous trials of 
venous ulceration (including the ESCHAR trial). This is likely to reflect the reluctance 
and apprehension of elderly patients to undergo surgical interventions involving 
general anaesthesia. The modern management of superficial venous disease 
involves a range of minimally invasive, endovenous modalities that can be performed 
using local or no anaesthesia. Procedures are performed on an outpatient basis and 
can be completed in around 30 minutes. Published studies of endovenous 
interventions have demonstrated excellent patient satisfaction and few treatment 
refusals. Due to the published evidence and extensive personal experience among 
the research team, we believe that the rate of participation will be higher and rate of 
protocol violations will be lower than previous studies. 
 
The following will be recorded as protocol deviations: 
1) Patients randomised to multilayer compression plus early venous reflux 
ablation, who receive endovenous intervention more than two weeks from 
randomization. 
2) Patients who are non-compliant with compression bandaging, defined as use 
<75% of the prescribed duration. 
3) Patients randomised to compression bandaging alone who undergo 
endovenous ablation prior to verified healing. 
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8. ADVERSE EVENTS  
8.1 REPORTING PROCEDURES  
All serious adverse events and all intervention-related adverse events should be 
reported. Depending on the nature of the event the reporting procedures below 
should be followed. Any questions concerning adverse event reporting should be 
directed to the Chief Investigator in the first instance.  
8.2 RELATED ADVERSE EVENTS 
Patients randomised to early venous intervention have the potential risks of 
treatment. Competent, experienced medical staff will perform all procedures and 
every effort will be made to prevent adverse effects. 
Radiofrequency or laser ablation may cause: 
 some short-term side effects such as numbness or pins and needles 
(paraesthesia). 
 some tightness in your legs and the affected areas may be bruised and painful. 
 nerve injury is also possible, but usually only temporary. 
  
Sclerotherapy can have side effects, including: 
 blood clots in other leg veins (DVT) 
 headaches 
 changes to skin colour, such as, brown patches over the treated veins  
 fainting 
 temporary vision problems 
 
After any of these procedures, it is possible the patient may develop a painful lump 
over the varicose veins, known as phlebitis, which may require treatment with 
antibiotics and/or drainage. 
8.3 NON SERIOUS ADVERSE EVENTS  
All such events, which are judged by the local PI to be related to the interventions, 
whether expected or not, should be recorded.  
8.4 SERIOUS ADVERSE EVENTS 
In addition to clinical assessments, patients will be contacted on a monthly basis by 
telephone for the duration of the study to identify any additional treatments, 
admissions or other complications related to their leg ulceration. Unrelated serious 
adverse events will also be recorded and reported in accordance with the Good 
Clinical Practice guidance. Serious adverse events (SAE) are defined as those 
adverse events that: result in death; are life-threatening; require in-patient 
hospitalisation or prolongation of existing hospitalisation; result in persistent or 
significant disability or incapacity; result in congenital anomaly or birth defect; are 
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cancer; or are other important medical events in the opinion of the responsible 
investigator (i.e. not life threatening or resulting in hospitalisation, but may jeopardise 
the participant or require intervention to prevent one or more of the outcomes 
described previously). 
All SAEs reported by participants at (or between) each follow-up visit will be 
recorded by local researchers in the clinical research form. Any SAE that is 
considered, with a reasonable probability, to be due to study intervention (i.e. 
superficial venous ablation) should be reported to the local PI (or their designated 
deputy) and to the trial coordinator. Such intervention-related SAEs will be reported 
by the trial coordinators to the Sponsor, Chair of the Data Monitoring Committee and 
to the relevant Ethics Committee. 
Contact details for reporting Intervention-related SAEs  
Fax: 0203 311 7362, attention Francine Heatley  
Please send SAE forms to: Francine Heatley  
Tel: 0203 311 7371 (Mon to Fri 09.00 – 17.00)  
 
  
EVRA Protocol Version 1.0  Dated: 19/06/2013 
Approved by The NRES Committee South West - Central Bristol REC on 15/08/2013 
24 
 
9. REGULATORY ISSUES  
9.1 ETHICS APPROVAL  
After approval from the Research Ethics Committee, the study must be submitted for 
Site Specific Assessment (SSA) at each participating NHS Trust. The Chief 
Investigator will require a copy of the Trust R&D approval letter before accepting 
participants into the study. The study will be conducted in accordance with the 
recommendations for physicians involved in research on human subjects adopted by 
the 18th World Medical Assembly, Helsinki 1964 and later revisions.  
 
9.2 CONSENT  
Consent to enter the study must be sought from each participant only after a full 
explanation has been given, an information leaflet offered and time allowed for 
consideration. Signed participant consent should be obtained. The right of the 
participant to refuse to participate without giving reasons must be respected. After 
the participant has entered the study the clinician remains free to give alternative 
treatment to that specified in the protocol at any stage if he/she feels it is in the 
participant’s best interest, but the reasons for doing so should be recorded. In these 
cases the participants remain within the study for the purposes of follow-up and data 
analysis. All participants are free to withdraw at any time from the protocol treatment 
without giving reasons and without prejudicing further treatment.  
 
9.3 CONFIDENTIALITY  
The Chief Investigator will preserve the confidentiality of participants taking part in 
the study and is registered under the Data Protection Act.  
 
9.4 INDEMNITY  
Imperial College London holds negligent harm and non-negligent harm insurance 
policies, which apply to this study. 
 
9.5 SPONSOR  
Imperial College London will act as the main Sponsor for this study. Delegated 
responsibilities will be assigned to the NHS trusts taking part in this study.  
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9.6 FUNDING  
The study is funded by the NIHR as part of the HTA programme. 
9.7 QUALITY ASSURANCE AND CONTROL  
The study may be subject to inspection and audit by Imperial College London under 
their remit as sponsor and other regulatory bodies to ensure adherence to GCP and 
the NHS Research Governance Framework for Health and Social Care (2nd edition). 
Quality Control will be performed according to the requirements of the Risk 
Assessment performed by ICTU. The study may be audited by a Quality Assurance 
representative of the Sponsor. All necessary data and documents will be made 
available for inspection. 
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10. STUDY MANAGEMENT 
The study will be coordinated by a trial manager based at ICTU reporting to the 
Clinical Coordinators (MG and RB) and the Chief Investigator (AD). The Clinical 
Coordinators will liaise with local principal investigators (L-PI) to ensure that the trial 
is conducted locally according to protocol and in an expeditious manner. The 
organisational structure and responsibilities are outlines below.  
10.1 PRINCIPAL INVESTIGATORS 
The chief investigator and clinical coordinators have overall responsibility for: 
 Design and conduct of the study 
 Preparation of the Protocol and subsequent revisions 
 Managing the Trial Coordinating Centre 
 Development of SOPs 
10.2 TRIAL STEERING COMMITTEE 
A Trial Steering Committee (TSC) will be established in line with HTA guidance, 
consisting of the chief investigator, clinical coordinators, trial manager, trial 
statistician, patient representative, an independent chair and at least 1 other 
independent member will be formed and will meet on a 6-monthly basis to discuss 
trial progress. The TSC is responsible for: 
 Agreement of the final Protocol 
 Agreeing the Data Analysis Plan 
 Reviewing progress of the study and, if necessary, agreeing changes 
to the Protocol 
 Reviewing new studies that may be of relevance 
 Review and approval of study reports 
10.3 DATA MONITORING COMMITTEE 
The independent Data Monitoring Committee (DMC) will be established in line with 
HTA guidance will focus on the rights, safety and well being of study participants. 
DMC responsibilities are: 
 Reviewing unblinded interim data according to the schedule outlined in 
the Protocol 
 Advising the Steering Committee if, in their view, the randomized data 
provide evidence that may warrant early termination for either safety or 
efficacy. 
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10.4 TRIAL COORDINATING CENTRE 
The Trial Coordinating Centre (TCC) is responsible for the overall coordination of the 
Study, including: 
 Study planning and organisation of Steering Committee meetings 
 Agreement of each local recruitment plan 
 Contractual issues with local study sites 
 Ethics Committee applications 
 Design, implementation and maintenance of IT systems for the study 
 Auditing and monitoring of overall progress of the study 
 Clinical safety monitoring (including the reporting of all “related” SAEs 
to the Chair of the DMC and Ethics Committee) 
 Liaison with the Data Monitoring Committee and (where appropriate) 
with regulatory authorities and other outside agencies 
 Responding to technical and administrative queries from local study 
sites 
10.5 LOCAL STUDY SITES 
The local principal investigators (L-PI) and clinical staff at the local study sites are 
responsible for: 
 Obtaining local R&D and management approval (aided by the Trial 
Coordinating Centre) 
 Provision of adequate clinic space and the identification of potentially 
eligible participants 
 Conducting study procedures and follow-up according to study protocol 
 Dealing with routine enquiries from participants and their families 
 Obtaining appropriate information to confirm potential primary and 
secondary study endpoints 
 Attend annual EVRA Study Collaborator Meetings to discuss study 
progress 
 
11. DOCUMENT RETENTION 
Data will be stored for a minimum of 10 years following completion of this trial. Data 
generated by this work will be processed in accordance with the Data Protection Act 
1998. 
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12. PUBLICATION POLICY  
The findings will be disseminated to General Practitioners, nursing staff, surgeons 
and other health care professionals at regular research and educational meetings 
organised at local, regional, national and international levels. All analyses will be 
performed in compliance with a predefined analysis plan. The chief investigator, 
clinical coordinators and trial coordinator will be responsible for drafting the main 
reports from the study. Draft copies of any manuscripts will be provided to local 
principal investigators at each local study site, TSC members and all other 
collaborators for review prior to publication. The results will be put forward for critical 
peer review with a view to publication in relevant medical and nursing journals. 
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Appendix 1: Summary of assessments and follow-up visits  
 
Time point Estimated 
duration 
(mins) 
Clinical 
evaluation
a
 
Telephone 
follow-up
b 
Wound 
review / 
tracing 
Wound 
photo 
Venous 
duplex 
Randomisation  Consent  Health 
Questionnaires 
(EQ-5D, SF-36, 
AVVQ)  
Screening Visit 45 X    X  X*  
Baseline Visit 60-90 X  X X  X  X** X 
1 month  30  X       
6 weeks 60-90 X  X? X X
c
   X 
2 months 30  X X? X?     
3 months 30  X X? X?     
4 months 30  X X? X?     
5 months 30  X X? X?     
6 months 30  X X? X?    X 
7 months 30  X X? X?     
8 months 30  X X? X?     
9 months 30  X X? X?     
10 months 30  X X? X?     
11 months 30  X X? X?     
12 months 30  X X? X?    X 
a. Demographic details (age, sex, ethnicity), Pregnancy test for woman of child bearing potential. General clinical details (body mass index, ankle brachial pressure index – performed within previous 4 weeks, comorbidities, medication history). Ulcer details 
(duration, progression, previous ulcer history, size of current ulcer – using photography and planimetry). Details of venous disease (previous deep vein thrombosis, previous venous interventions, pattern of venous reflux on duplex) 
b. . Ulcer healing assessment, compression type, AE assessment, Concomitant medications, health resource use 
c. Only for those who have early endovenous treatment 
*Approached    **Taken    
?dependant on whether the ulcer has healed tracing and photo will be taken at verification visit and taken weekly for 1 month. Once the ulcer has healed the patient will still be followed up with monthly phone calls. 
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Revision History 
 
Protocol Version Date  Amendments 
V5.0 06/04/2017 
To incorporate the HTA funding extension to the trial to allow 
for the collection of longer term follow-up during October 2018 
and March 2019 
Amendments to the health economics section to clarify some 
items which were unclear in the previous version, and update 
the protocol to reflect new NIHR guidelines. 
V4.0 16/03/2016 
To correct sample size from 500 participants to 450 participants 
which was originally calculated erroneously 
To allow for a reduction in the number of photo verification 
visits performed if the core lab confirms the ulcer is healed. 
V3.0 10/03/2014 
Amended in order to display posters, leaflets and disseminate 
patient information sheets in primary care sites 
V2.0 06/01/2014 
A clearer definition of ulcer healing is required to clarify that 
healing cannot be assume if a scab is present. 
Statistics and Data Analysis’ section amended for clarity of per-
protocol analyses. 
Serious adverse event (section 8.2) amended for clarity. 
Section 5.4 amended to clarify that patients can be offered 
intervention in the standard care (compression arm) if their 
ulcer has not healed at 6 months. 
V1.0 19/06/2013 
 
N/A – Original Protocol 
 
Study Management Group  
Chief Investigator: Professor Alun H Davies 
Co-investigators: Mr Manjit S Gohel, Mr Richard Bulbulia, Mr Keith R Poskitt, Professor 
Andrew Bradbury, Professor Nicky Cullum, Miss Sophie R Renton, Mr I Nyamekye 
Statistician: Dr Jane Warwick 
Health economist: Dr David Epstein 
Study Management: Miss Francine M Heatley 
Study Coordination Centre  
For general queries, supply of study documentation, and collection of data, please contact:  
Study Coordinator: Miss Francine M Heatley 
Address: Vascular Surgery Research Group, Room 4E3, 4th Floor East Wing 
Charing Cross Hospital, Fulham Palace Road, London W6 8RF 
Tel: 020 3311 7371 
E-mail: f.heatley@imperial.ac.uk 
Web address: www.evrastudy.org 
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Clinical Queries  
Clinical queries should be directed to either the Local PI or the Study Coordinator who will 
direct the query to the appropriate person  
 
Sponsor  
Imperial College London is the main research Sponsor for this study. For further information 
regarding the sponsorship conditions, please contact the Head of Regulatory Compliance at:  
Joint Research Compliance Office  
Imperial College London and Imperial College Healthcare NHS Trust 
Room 215, Level 2, Medical School Building 
Norfolk Place 
London, W2 1PG 
Tel: 0207 594 1872  
 
This protocol describes the EVRA study and provides information about procedures 
for entering participants. Every care was taken in its drafting, but corrections or 
amendments may be necessary. These will be circulated to investigators in the study. 
Problems relating to this study should be referred, in the first instance, to the Chief 
Investigator.  
This study will adhere to the principles outlined in the NHS Research Governance 
Framework for Health and Social Care (2nd edition). It will be conducted in compliance 
with the protocol, UK Clinical Trials Regulations, the Data Protection Act and other 
regulatory requirements as appropriate.  
 
 
This project is funded by the National Institute for Health Research HTA (project 
number 11/129/197). The views and opinions expressed therein are those of the 
authors and do not necessarily reflect those of the HTA, NIHR, NHS or the 
Department of Health. 
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ABBREVIATIONS 
 
AE Adverse Event 
CI Chief Investigator 
CRF Case Report Form 
DMC Data Monitoring Committee 
ICTU Imperial Clinical Trials Unit 
REC Research Ethics Committee 
QA Quality Assurance 
SAE Serious Adverse Event 
SAP Statistical Analysis Plan 
SOP Standard Operating Procedure 
SUSAR Suspected Unexpected Serious Adverse Reaction 
TSC Trial Steering Committee 
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1. INTRODUCTION  
1.1 BACKGROUND  
Chronic leg ulcers are open “sores” on the lower limbs situated between the ankles 
and knees, which fail to heal within 6 weeks. These ulcers represent a source of 
great discomfort and social isolation to patients who often complain of associated 
pain, odour and wound discharge. The time taken for the ulcers to heal means that 
the condition is also particularly frustrating to health carers involved in their 
management in hospital and community settings. The underlying cause of leg 
ulceration in over 70% of cases is lower limb venous dysfunction, sometimes evident 
as varicose veins but often undetectable by visual examination alone1. The 
estimated overall prevalence of active venous ulceration is as high as 1.5 to 1.8 per 
1000 population, increasing to 3.8 per 1000 population in those over 40 years of 
age23. As patients with venous ulceration usually suffer episodes of recurrence 
between periods when the ulcer remains healed, the number of patients with a high 
risk of ulceration may actually be 4-5 fold higher4. It should also be noted that with an 
aging and increasingly obese population5, the incidence and prevalence of venous 
ulceration are both likely to increase. Treatment of the condition in the UK produces 
a substantial cost burden estimated at £400-600 million per annum6. 
Venous ulcers are characterised by protracted healing times. Despite some recent 
advances in the management of patients with venous ulcers, 24 week healing rates 
in published randomised trials are around 60-65%78, and the true population healing 
rates are likely to be significantly lower. Some patients may never heal and those 
that do heal are at high risk of recurrent ulceration. These poor outcomes are likely 
to be a reflection of the severe underlying venous dysfunction in this patient group, 
although inadequate assessment and suboptimal treatment are also likely to be 
important contributing factors. 
1.1.1 Pathophysiology of venous ulceration 
The venous circulation of the lower limb has two components, the deep and 
superficial systems. Blood normally flows from the superficial to the deep veins and 
is prevented from flowing back down the leg under the influence of gravity by ‘one-
way’ valves along the veins. When these valves become incompetent (leaky), the 
superficial veins usually become dilated and tortuous (varicose) and the resulting 
sustained high venous and capillary pressures lead to skin inflammation and 
ulceration (breakdown of skin). The deep veins also have valves, which may also 
become incompetent, but are not visible on the skin. Duplex ultrasound studies91011 
on patients in leg ulcer clinics suggest that: 
 Around 50% of patients with venous leg ulcers have diseased superficial veins 
alone, with a further 30-40% having a mixture of superficial and deep venous 
disease. Both of these groups of patients benefit from correction of their 
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superficial venous reflux, which has been shown to reduce the risk of ulcer 
recurrence12. 
 A minority (5-10%) of patients with venous ulcers have diseased deep venous 
systems only, and are not amenable to surgical correction. These patients are 
usually treated with compression bandaging alone 
Ulcer healing strategies are based on efforts to reduce this leakage (reflux) of blood 
back down the leg and into the skin, as this is considered the most significant cause 
of high venous pressure in most patients. Longstanding venous hypertension has 
been shown to cause a number of changes to the microcirculation in the lower leg, 
which can contribute to the chronic skin changes or eventual ulceration associated 
with chronic venous disease13. Compression bandaging to the leg (which may need 
to be re-applied 1-4 times per week) counteracts the gravitational force on the blood, 
in effect temporarily replacing the incompetent valves14. Diseased superficial veins 
can be surgically removed (open varicose vein surgery) or ablated using 
endovenous interventions (see below) without harming the overall venous function of 
the leg, theoretically removing a causative factor for recurrence of the ulcer after the 
compression bandaging has ceased. The deep vein defects are not generally 
amenable to surgery. 
1.1.2 Treatment options for superficial venous reflux 
For over a century, the treatment of superficial venous reflux has involved operative 
ligation and surgical stripping of the vein and avulsion of bulging varicose veins15. 
Until recent years, open surgery has been considered the definitive treatment option 
for superficial venous reflux. However, the operation usually requires general 
anaesthesia and patients often suffer discomfort, bruising and significant time off 
work in the post-operative period. Long-term studies have also identified significant 
complications of open surgery including nerve damage and recurrence of varicose 
veins, seen in over 60% of patients at 11 years in one randomised study16.  
In response to this high complication rate and a growing patient desire for less 
invasive treatments, a range of novel, minimally invasive endovenous treatment 
options have been developed and have gained in popularity over the last decade. 
Interventions such as ultrasound guided foam sclerotherapy (UGFS)17, endovenous 
laser (EVLA)18 or radiofrequency ablation (RFA)19 can be performed using local 
anaesthesia in an outpatient setting. These treatments involve cannulation of the 
vein to be treated (usually under ultrasound guidance) and obliteration of the venous 
channel by either chemical ablation (using foam sclerosant), or thermal ablation 
(using a laser or radiofrequency fibre). Numerous randomised studies have 
demonstrated that endovenous modalities are, at worst, comparable to open surgery 
in terms of recurrence (and likely to be better), but clearly superior in terms of pain, 
bruising and other early complications20-22. Each of the different endovenous 
modalities has advantages and potential disadvantages, although all are less 
invasive than traditional open surgery. This is of particular relevance to patients with 
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chronic venous ulceration, who are often elderly, have extensive co-morbidities and 
may be reluctant to undergo surgical procedures involving general anaesthesia. 
Endovenous techniques can also be performed without discontinuing anti-
coagulation therapy, which is increasingly prescribed in this patient population. 
1.1.3 Summary of current research 
The most significant study of superficial venous intervention in patients with venous 
ulceration is the ESCHAR study (Barwell, Poskitt; Lancet 2004 & Gohel, Poskitt; 
BMJ 2007)712. The study aimed to evaluate the role of traditional superficial venous 
surgery in reducing ulcer recurrence in patients with open or recently healed venous 
ulcers. Following prospective observational studies to inform power calculations, a 
total of 500 patients were randomised to compression therapy alone or compression 
with open surgery for superficial venous reflux. The group randomised to surgical 
treatment had significantly lower venous ulcer recurrence rates at 4 years (Figure 1).  
Analysis stratified by pattern of venous reflux demonstrated that this clinical benefit 
was present for patients with isolated superficial venous reflux and patients with 
superficial and segmental deep reflux. This clearly indicated that the majority of 
patients with chronic venous ulceration could benefit from superficial venous 
intervention. As a result, the current optimal management of patients with venous 
ulceration includes the treatment of refluxing superficial veins to reduce the risk of 
ulcer recurrence23.  
Analysis of ulcer healing within the ESCHAR trial demonstrated that there was no 
significant improvement in ulcer healing rates for the group randomised to 
compression plus surgery (Figure 2). This finding has led many to conclude that 
treatment of venous reflux does not have a role in patients with open ulcers.  
 
 
 
 
 
 
 
 
 
However, the ESCHAR study was designed and powered to assess ulcer recurrence 
rather than healing, and the statistical power of this trial was further weakened by a 
high cross-over rate, as around a quarter of patients randomised to surgery 
subsequently refused to have an operation. This highlights the need for a minimally 
invasive superficial venous treatment modality in this patient group. In addition, the 
Figure 1. ESCHAR trial – ulcer 
recurrence 
Figure 2. ESCHAR trial – ulcer 
healing 
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median time to treatment within the study was around 2 months, by which time 
smaller ulcers may have already healed with compression bandaging, and, in many 
cases, the surgical procedures used were suboptimal when judged by current 
standards. Consequently, it is plausible that the benefits of treating superficial 
venous reflux were underestimated in this study, particularly for the assessment of 
ulcer healing.  
In a smaller Dutch randomised trial, 170 patients (200 legs) were randomised to 
compression alone or compression with surgical treatment of superficial reflux 
(including subfascial endoscopic perforator surgery – SEPS)8. Although results did 
not reach statistical significance, there was a clear trend towards improved ulcer 
healing rates and greater ulcer free time in the group randomised to surgery.  
Despite the widespread acceptance of endovenous modalities, few prospective 
studies have been published reporting outcomes after endovenous treatment in 
patients with leg ulcers. In a prospective study of 186 patients with leg ulceration 
treated with UGFS, the ulcer healing rate was over 70% and the patient acceptability 
of treatment was excellent (Poskitt et al)24. In a further study of foam sclerotherapy in 
130 patients, a healing rate of 82% was achieved (Bradbury et al)25. Whilst these 
small non-randomised studies lend support to our hypothesis that early intervention 
to correct superficial venous reflux will promote ulcer healing, a large randomised 
trial is required to provide reliable evidence and thus change practice. 
 
1.2 RATIONALE FOR CURRENT STUDY 
Whilst the management of patients with venous ulcers has evolved in recent years 
and ulcer healing and recurrence rates have shown some improvement, we believe 
that there is a strong argument in favour of this study at this time for the following 
reasons: 
 The prevalence of venous ulceration is likely to increase, particularly with an 
aging and increasingly obese population. In view of the significant financial and 
psychosocial costs of venous ulceration, it is imperative that the optimal 
treatment strategies are identified.  
 Despite numerous studies of topical ulcer treatments, the only treatment shown 
to improve venous ulcer healing is compression bandaging. Compression 
supports the venous circulation, but is poorly tolerated by some patients and 
does not address the underlying problem of venous reflux. The intervention in this 
proposal involves treating the underlying anatomical venous disorder using 
effective, minimally invasive endovenous interventions and offers a logical, 
deliverable and long-term approach to reducing venous hypertension.   
 The treatment of superficial venous reflux has been transformed in recent years 
through the widespread use of minimally invasive, endovenous interventions, 
which patients find more acceptable than traditional open surgery. 
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 Ablation of superficial reflux should be considered in all patients with leg ulcers 
and superficial venous reflux, but if early intervention is associated with moderate 
improvements in ulcer healing compared to deferred intervention (i.e. post-
healing), significant cost savings could be realised.  
 Patients find venous leg ulcers painful, distressing and a significant inhibition to 
normal, independent life. Interventions to reduce the time to healing could reduce 
patient distress and significantly improve quality of life.  
Therefore, we believe that there is a cogent argument for conducting this trial at this 
time. Non-randomised studies suggest that outcomes may be improved by treating 
underlying superficial reflux using the latest technologies, but there is no robust 
evidence to support early intervention. The research team has a strong track record 
in relevant research areas and includes clinicians and researchers who successfully 
completed the landmark clinical trial on which this proposal is based (ESCHAR trial), 
and numerous other high impact clinical trials evaluating treatments in venous 
ulceration. 
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2. OBJECTIVES 
2.1 PRIMARY OBJECTIVE 
To determine the clinical and cost effectiveness of early endovenous treatment of 
superficial venous reflux in addition to standard care compared to standard care 
alone in patients with chronic venous ulceration. 
 
2.2 SECONDARY OBJECTIVES 
To investigate: 
 The ulcer free time to 1 year and with the extension, up to 5 years (median of 
approximately 3.7 years) 
 The technical success of endovenous interventions 
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3. PARTICIPANT ENTRY  
3.1 PRE-REGISTRATION EVALUATIONS  
Prior to commencing, information will be disseminated to GP practices in each 
recruiting region and meetings will be arranged with key community nursing staff and 
at leg ulcer clinics to promote the trial. Patients will be referred to secondary care as 
part of the standard care pathway as per the July 2013 NICE Guidelines. To aid 
recruitment, selected Primary Care trusts not currently involved in the trial will be set-
up as Patient Identification Centres (PIC sites) displaying posters, leaflets and 
disseminating patient information sheets to patients.  Selected Primary Care trusts 
involved in follow-up of the trial (research sites) will also aid recruitment by displaying 
posters, leaflets and disseminating patient information sheets to patients. Patients 
will still need to be referred to the secondary care recruiting sites to be consented 
and randomised into the trial.   
At the referral visit patients will be given an appropriate time period to consider 
participation (at least 24 hours). Written consent will be obtained from those patients 
who agree to participate and randomization will be performed using the online 
service. For patients randomised to endovenous ablation of superficial venous reflux, 
a date for intervention will be booked as soon as possible (i.e. within 2 weeks). At 
each recruiting centre, an online log of all screened patients will be kept using the 
InForm system. Basic demographic data and reasons for non-eligibility will be 
recorded. Whilst participant baseline characteristics may vary slightly across 
recruiting sites, randomised treatment allocation will allow reliable assessment of the 
effects of early versus delayed endovenous ablation in ulcer healing. 
3.2 INCLUSION CRITERIA  
 Current leg ulceration of greater than 6 weeks, but less than 6 months duration 
 Able to give informed consent to participate in the study after reading the patient 
information documentation 
 Patient age > 18 years 
 Ankle Brachial Pressure Index (ABPI) ≥ 0.8 
 Superficial venous disease on colour duplex assessment deemed to be 
significant enough to warrant ablation by the treating clinician (either primary or 
recurrent venous reflux) 
Patients who cannot speak / understand English will be eligible for inclusion and 
informed consent will be obtained with assistance from translation services as per 
standard clinical practice. In view of the lack of cross-cultural validation for quality of 
life tools, only healing outcome data will be collected. 
3.3 EXCLUSION CRITERIA  
 Presence of deep venous occlusive disease or other conditions precluding 
superficial venous intervention (at the discretion of local research team) 
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 Patients who are unable to tolerate any multilayer compression bandaging / 
stockings will be excluded. However, concordance with compression therapy can 
be variable for patients at different times. Patients who are generally compliant 
with compression, but unable to tolerate the bandages for short periods will still 
be eligible to inclusion. A period of non-compliance with compression bandages 
will not be considered a protocol violation, but a normal variation within the 
spectrum of ‘standard therapy’.  
 Inability of the patient to receive prompt endovenous intervention by recruiting 
centre 
 Pregnancy (female participants of reproductive age will be eligible for inclusion in 
the study, subject to a negative pregnancy test prior to randomisation) 
 Leg ulcer of non-venous aetiology (as assessed by responsible clinician) 
 If patient is deemed to require skin grafting they cannot be included 
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4. STUDY DESIGN  
The EVRA ulcer trial is a pragmatic; multicentre randomised clinical trial with 
participants randomised1:1 to either: 
1. ‘Standard’ therapy consisting of multilayer elastic compression bandaging/ 
stockings with deferred treatment of superficial reflux (usually once the ulcer has 
healed) 
2. Early endovenous treatment of superficial venous reflux(within 2 weeks) in 
addition to standard therapy 
The study design is summarised in Figure 3 below.  
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4.1 PATIENT RANDOMIZATION 
The normal clinical team will make initial contact with potentially eligible patients at 
the referral visit.  
Those who consent will be registered on the InForm ITM (Integrated Trial 
Management) System, a web-based data entry system, which is maintained by ICTU, 
and their eligibility for the study confirmed.  A randomization list will be loaded onto 
the InForm system for each centre (as stratification will be by centre) before 
recruitment commences, having been prepared in advance by a statistician who is 
independent of the study. Each potential participant, if confirmed to be eligible, will 
be assigned the next available entry in the appropriate randomization list (i.e. without 
foreknowledge). Thereafter, treatment allocation will not be blinded (with the 
exception of assessment of ulcer healing – see 4.3.1). For patients with bilateral 
venous ulceration, the worst leg (according to the patient) will be designated the 
‘reference leg’. Interventions may be performed on both legs, if deemed appropriate 
by the responsible clinician. 
4.2 STUDY SETTING 
Eligible patients with chronic venous ulcers will initially be recruited from the 
following centres: 
1. Imperial College Healthcare NHS Trust (PI: Professor AH Davies) 
2. Cambridge University Hospitals NHS Foundation Trust (PI: Mr MS Gohel) 
3. Worcestershire Acute Hospitals NHS Trust (PI: Mr I Nyamekye) 
4. North West London Hospitals NHS Trust (PI: Miss SR Renton) 
5. Gloucestershire Hospitals NHS Foundation Trust (PI: Mr KR Poskitt) 
6. Heart of England NHS Trust (PI: Professor A Bradbury) 
7. University Hospital Birmingham NHS Trust (PI: Mr Rajiv Vohra) 
8. City and Sandwell NHS Trust (PI: Miss Rachel Sam) 
9. The Dudley Group NHS Trust (PI: Mr Andrew Garnham) 
10. The Royal Wolverhampton Hospitals NHS Trust (PI: Mr Andrew Garnham) 
11. York Hospitals NHS Foundation Trust 
12. Hull & East Yorkshire Hospitals NHS Trust 
13. The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust 
14. Frimley Park Hospital NHS Foundation Trust 
15. Plymouth Hospitals NHS Trust 
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16. Bradford Teaching Hospitals NHS Foundation Trust 
17. Salisbury NHS Foundation Trust 
18. Leeds Teaching Hospitals NHS Trust 
19. Sheffield Teaching Hospitals NHS Foundation Trust 
20. Taunton and Somerset NHS Foundation Trust  
As per section 3.1 Primary Care Trusts will be set-up as either PIC sites or research sites 
aiding recruitment by displaying posters, leaflets and disseminating patient information 
sheets. Patients will still need to be referred to the secondary care recruiting sites to be 
randomised into the trial.   
4.3STUDY OUTCOME MEASURES 
4.3.1 Primary outcome measure 
The primary outcome measure will be time to ulcer healing (from date of 
randomization to date of healing). For the purposes of this study, ulcer healing is 
defined as complete re-epithelialisation of all ulceration on the randomised 
(reference) leg in the absence of a scab (eschar) with no dressing required. 
Community or hospital healthcare staff, depending on the local model of care, will 
perform assessment of ulcer healing.  
Data on the status of the reference leg will be collected throughout the study by 
research staff scrutinising community medical / nursing records and contacting the 
patient / community nursing teams by telephone(on a monthly basis at least). 
If either the community nursing / medical staff or the patient believe that ulcer healing 
has been achieved, they will be asked to contact the local research centre 
immediately. This notification of possible ulcer healing will constitute a ‘trigger’ forth 
research staff at the recruiting centre to arrange an urgent verification assessment 
by a member of the healthcare team (within 1 week). 
Verification will be by clinical assessment and digital photography, to be repeated 
weekly for 4 weeks, unless otherwise agreed by the trial manager. The digital 
images will be evaluated by two blinded expert assessors in order to ascertain the 
date of healing, which will be considered the primary healing end-point. For the 
purposes of the trial healing will be defined as the complete re-epithelialisation of the 
ulcerated (reference) leg in the absence of a scab (eschar) with no dressing required. 
Healing cannot be assumed if a scab present.  
Disagreements will be resolved through discussion with involvement of a third 
blinded expert reviewer if necessary. This approach will be applied to patients in both 
treatment arms and is consistent with the methods utilized in other large HTA funded 
leg ulcer trials (e.g. VenUS IV). Legs deemed to have an open ulcer on clinical 
assessment would continue within the study. If healing is confirmed by clinical and 
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blinded photograph assessments at the first verification visit, the date of healing 
notification (by patient or community nurse) will be taken as the date of ulcer healing. 
4.3.2 Secondary outcome measures 
A number of secondary outcome measures will be evaluated in the EVRA study: 
1. Ulcer Healing Rate: Healing rate will be reported at 24 weeks in addition to time 
to ulcer healing to allow comparison with other published studies.  
2. Ulcer recurrence / Ulcer Free Time: Will be calculated up to 1 year for each study 
arm and with the extension, up to 5 years (median approximately 3.7 years). This 
will allow a very practical and easily understood assessment of the clinical 
difference between the 2 arms of the study. This will also allow comparison with 
other studies that have reported this outcome. In order to facilitate accurate 
calculation of reoccurrence / ulcer free time, clinical follow up will be continued 
after ulcer healing up to 1 year after randomisation. 
3. Quality Of Life (QoL): Disease specific (AVVQ) and generic (EQ5D & SF36) 
quality of life assessments will be compared at 6 weeks post randomisation, 6 
months, 12 months and at one time point between October 2018 and March 2019. 
The 6-week questionnaire will be given to the patient at the follow-up 
appointment, whereas other QoL questionnaires will be sent to the patient or 
completed by the patient via telephone. AVVQ is the most widely utilised disease 
specific QoL tool in venous disease and has been extensively validated. A score 
out of 100 points is calculated, with a higher score indicating more severe QoL 
impairment. Changes in QoL scores will offer a comparison with other studies 
and, in the standard treatment arm, will allow an assessment of the natural 
history of venous ulceration treated with compression.  
4. Health Economic Assessment: A within-RCT cost effectiveness analysis will be 
carried out based on the data collected in the trial, Resource use items in hospital 
and community care related to the treatment of venous ulceration or 
complications will be recorded for each patient at each follow-up. Resource use 
will be multiplied by UK unit costs obtained from published literature, HRG costs, 
and manufacturers’ list prices to calculate overall costs. A standard tariff will be 
applied for each bandage change. Utilities (QALYs) will be calculated from the 
EQ-5D questionnaire administered to patients at baseline, 6 weeks, 6 months, 12 
months and at one time point between October 2018 and March 2019. The extent 
of missing data will be assessed and appropriate methods to handle missing data 
will be applied if necessary.  The incremental cost-effectiveness ratio will be 
calculated and compared to current UK decision making thresholds. Discounting 
will be applied at the standard rate. Sensitivity analysis will be carried out to test 
the robustness of results to alternative assumptions (for example, about missing 
data, or using per-protocol estimates of treatment effect) or alternative data (for 
example, about unit costs). Probabilistic sensitivity analysis will be carried out 
using bootstrapping. A decision model will also be constructed to take account of 
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outcomes (such as recurrence or healing) that might occur beyond time horizon 
of the RCT, or to take account of other relevant comparators in this patient group.    
5. Other Markers of Clinical Success: The Venous Clinical Severity Score (VCSS) 
will be assessed at 6 weeks. In addition, the incidence of complications related to 
the endovenous intervention as well as the presence of residual / recurrent 
varicose veins will also be assessed at 6 weeks in the early arm.  
 
 
 
 
4.4 DURATION OF FOLLOW-UP 
In the original study, participants were to be followed-up until either: 
1. 1 year post-randomization 
2. Patient choice to withdraw from the study. Patients who no longer wish to 
complete quality of life questionnaires will be asked if they would object to the 
use of healing status data (to contribute to the primary outcome) 
3. Death 
In order to allow assessment of ulcer free time to 1 year, patients with healed ulcers 
were to be evaluated using telephone follow-up (performed by staff at the recruiting 
centre) on a monthly basis until 1 year. The aim of the telephone follow-up was to 
confirm that the ulcer remains healed, or in cases of ulcer recurrence, to ascertain 
the date of recurrence and of subsequent healing.  
In December 2016 The HTA approved an extension to the trial follow-up allowing the 
collection of follow-up data for all patients who have not withdrawn consent to the 
trial. Data collection will commence in October 2018, allowing a median follow-up 
period of up to 5 years (median approximately 3.7 years) to be obtained (further 
details given in section 6.6). 
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4.5 STUDY DURATION 
The EVRA study will take 70 months to complete. The revised study timetable is summarised in Figure 4. 
 
 
 
 
 
 
 
 
 
 
Figure 4. EVRA Study timeline
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5. DETAILS OF INTERVENTIONS 
5.1 VARIATIONS IN ENDOVENOUS INTERVENTIONS 
A wide range of endovenous treatment modalities are now available and in 
widespread use for the ablation of superficial venous reflux. These include: 
 Endovenous thermal ablation using laser or radiofrequency 
 Ultrasound guided foam sclerotherapy (UGFS) 
 Other endovenous interventions such as mechanochemical ablation, steam 
ablation and glue 
 Any combination of the above treatments 
In addition to the different modalities in use, the treatment strategy may also vary 
between institutions and between individual clinicians within the same department. 
Variations may occur in: 
 Site of vein cannulation (and therefore the length of vein ablated) 
 Location of treatment (‘office’ or clinic based versus operating theatre) 
 Treatment strategy for sub-ulcer venous plexus (to ablate or not) 
 The treatment of visible varicose veins (no treatment, UGFS or surgical 
avulsion) and the timing of any intervention 
5.2 STANDARDISATION OF INTERVENTIONS IN EVRA STUDY 
With the lack of consensus on a single, optimal endovenous treatment strategy for 
superficial reflux in patients with leg ulceration, perfect standardisation of 
interventions will be impossible. All endovenous interventions should be performed 
as deemed to be ‘optimal’ by the treating clinician for each individual patient, with the 
following stipulations: 
1. The endovenous strategy must include ablation of the main truncal venous 
reflux 
2. Truncal venous reflux should be treated to the lowest point of incompetence, 
where possible 
3. Significant (as deemed by the treating clinician) residual / recurrent superficial 
reflux on the 6 week duplex scan, should be ablated 
4. Patients should continue with multilayer compression / stockings immediately 
after treatment 
5.3 STANDARDISATION OF COMPRESSION 
Patients will receive the standard compression used in the individual centres prior to 
ulcer healing following randomisation (this will include four layer bandaging, three 
layer bandaging, European short stretch, stockings). Post healing the patients will be 
given compression hosiery in line with local policy.   
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5.4 FURTHER TREATMENT FOR STANDARD CARE (COMPRESSION 
ALONE) ARM 
Patients randomised to multilayer compression / stockings alone can be offered 
endovenous treatment of superficial reflux once healing has been confirmed or at 6 
month post randomisation (see 4.3.1). Endovenous ablation should be performed as 
per standard practice in the treating centre and details of this will be recorded. 
Endovenous intervention may also be offered if there is clinical deterioration in the 
active leg ulcer and it is clinically felt that the patient may benefit from early 
intervention. This will be recorded on the electronic case report form. 
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6. ASSESSMENT AND FOLLOW-UP  
6.1 PATIENT IDENTIFICATION 
Patients will be referred to secondary care for evaluation of the management of their 
leg ulcer as part of the standard pathway of care. 
6.2 REFERRAL VISIT 
At the initial visit the patient will be evaluated by clinical assessment and colour 
duplex examination, which is part of the normal investigation of a patient with leg 
ulceration. Dependant on the results of these tests, the patient will be asked if they 
would consider taking part in the trial and approached for consent. The patient will be 
given a minimum of 24 hours to consider the trial and if willing to participate will 
return to the leg ulcer clinic to give consent and undergo a baseline visit.  
6.3 BASELINE VISIT 
Patients will undergo detailed clinical assessment by the research nurse as part of 
the baseline evaluation (see Appendix 1). Recorded assessments will include: 
 Demographic details (age, sex, ethnicity) 
 Pregnancy test for woman of child bearing potential 
 General clinical details (body mass index, ankle brachial pressure index – 
performed within previous 4 weeks, comorbidities, medication history) 
 Ulcer details (duration, progression, previous ulcer history, size of current ulcer – 
using photography and planimetry) 
 Details of venous disease (previous deep vein thrombosis, previous venous 
interventions, pattern of venous reflux on duplex) 
Additional assessments will include: 
 Assessment of Clinical, Etiologic, Anatomic, Pathophysiological (CEAP) score 
 Assessment of venous clinical severity score (VCSS) 
 Disease specific (Aberdeen varicose vein questionnaire – AVVQ) and generic 
(EuroQoL 5D – EQ5D & short form (SF) 36) quality of life assessments  
At this visit, eligible and consenting patients will be randomised into the trial. 
6.4 FOLLOW-UP ASSESSMENTS 
Randomised patients will undergo routine leg ulcer care in community or hospital (or 
both) settings, in accordance with the local standard. This will equate to wound 
reviews and dressing changes ranging between once and 4 times per week 
(depending on the ulcer). The exact nature of dressings and date of dressing change 
will be documented by the completion of patient diaries. This will allow an accurate 
record of the dressing types used and will be collected and verified by the research 
nurse. 
In addition, the following assessments will be conducted: 
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6.4.1 6-week clinic visit 
 Clinical assessment 
 In the compression plus early venous reflux ablation group, venous duplex 
scanning will be performed at 6 weeks post-randomization to verify anatomical 
treatment success. Depending on the results of the scan, the decision to perform 
further superficial venous interventions will be left to the discretion of the 
responsible clinical staff. Irrespective of the number and timing of venous 
interventions, all analyses will be performed on intention to treat. 
 Wound tracing and photo 
 Assessments of disease specific and generic quality of life (AVVQ, EQ5D & SF36) 
by means of self-completed questionnaire 
 
6.4.2 Further follow-up 
 Assessments of disease specific and generic quality of life (AVVQ, EQ5D & SF36) 
by means of self-completed questionnaire at 6 months and 12 months post-
randomization (sent to the patient). 
 The research team will perform monthly telephone evaluation of the patient and 
access the community notes or telephone the community nurses in order to 
collect and verify the data collected. 
 Once the research team has been informed that the ulcer has healed the patient 
will undergo an urgent verification visit 
 
6.5 URGENT VERIFICATION VISIT 
 A member of the local research team will perform the four verification visits to 
confirm healing. Photographs will be taken and send to the Trials Unit for 
independent verification. In order to minimise inconvenience to the 
participants, once core labs confirms healing it is not necessary for the 
research team to perform further verification visits. Please note all four photos 
should be taken unless the trial manager confirms otherwise. 
 
6.6 LONGER TERM FOLLOW-UP 
For each randomised patient a single telephone assessment will be performed 
between October 2018 and March 2019 to collect: 
 Details of any further ulcer recurrence and healing events 
 Assessment of ulcer related healthcare attendances and costs 
 Details of all further venous interventions performed and any associated 
adverse events 
 Assessments of disease specific and generic quality of life (AVVQ, EQ5D & 
SF36) by means of self-completed questionnaire completed over the 
telephone (or via post) 
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The research teams will also evaluate healthcare records to: 
 verify ulcer recurrence and healing events 
 obtain specific details about venous investigations and interventions 
performed including delays to intervention.  
 
No anatomical assessments of long-term treatment success are planned; however, 
additional treatments will be recorded and included in the health-economic 
evaluations. 
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7. STATISTICS AND DATA ANALYSIS 
Data and all appropriate documentation will be stored for a minimum of 10 years 
after the completion of the study, including the follow-up period in accordance with 
the Imperial College JCRO Archiving Study Documents SOP.  
7.1 SAMPLE SIZE CALCULATION 
The sample size calculation for this study was based on the primary outcome of 
ulcer healing. The ESCHAR trial was a similar randomised study, which published 
the final results in 2007 (see 1.1.3). A total of 500 patients with open or recently 
healed venous ulcers were randomised to standard therapy alone or standard 
therapy plus open surgery for superficial venous reflux. The study was powered and 
designed to evaluate differences in ulcer recurrence (rather than healing). 
Consequently, the median time from randomization to treatment delivery was over 7 
weeks. Nevertheless, the 24-week healing rate in patients randomised to standard 
treatment (compression alone) was approximately 60%. Two recent prospective 
studies evaluating the early treatment of superficial venous reflux suggested that the 
24-week healing rate may be as high as 82%24 25.  
In order to calculate a sample size for this study, a benefit associated with early 
treatment is estimated at around 15%. Assuming the 24-week healing rate in the 
standard arm is 60%, to identify a difference in 24-week healing rates of 15% 
between the two groups (60% vs 75%) with 90% power and allowing for 10% 
dropout the study will therefore require 416 subjects (208 in each arm, 254 healed 
leg ulcers in total). To incorporate further allowances for protocol violations and 
unexpected dropouts, the target sample size will be 450 patients. 
Assuming a 15% drop out rate for the study and that 90% of primary ulcers 
eventually heal, it is estimated that >340 of the recruited 450 patients will be eligible 
for inclusion in the ulcer recurrence analysis. With this number of participants, and 
allowing for the healing rates (of the index ulcer prior to entry into this analysis of 
ulcer recurrence) to differ by up to 20% between the two study arms, the study 
extension will have at least 80% power to detect a difference of 15% or more in ulcer 
recurrence rates between the two arms at the 5% significance level.  
 
7.2 PLANNED ANALYSES 
No formal interim analyses are planned. Informal interim analyses will be performed 
if requested by the Data Monitoring Committee (DMC) but findings will be made 
available to member of the DMC only. Basic descriptive methods will be used to 
present the data on study participants, trial conduct, clinical outcomes and safety (in 
total and for each study group separately). The primary outcome will be time to 
complete healing. We will test the hypothesis that there is no difference in time to 
complete healing between the control and intervention groups using a log-rank test 
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(two-tailed, 5% significance level). Kaplan-Meier survival curves will also be 
presented and we will perform a subsidiary analysis investigating the effect of study 
centre, participant age, ulcer size and chronicity on time to complete healing using 
Cox regression. To adjust for potential surgeon and centre effects, surgeon and 
centre will be included in the Cox regression analysis as random effects. All analyses 
will be on an intention-to-treat basis. If there is substantial cross-over, per-protocol 
analyses may be explored for sensitivity analyses. Safety and tolerability data will be 
presented by the two arms on an intention-to-treat basis. The statistical analysis plan 
(SAP) for the original trial (follow up to 1 year) will be finalised prior to the final 
analysis. An additional SAP for the extension follow-up (up to 5 years) will be 
finalised before the analysis of extension data. 
 
7.3 MISSING, UNUSED AND SPURIOUS DATA 
There will be no data imputation for missing data in the primary endpoint (time to 
healing) and the secondary endpoint of ulcer free time. Any imputation methods 
used may be proposed for purposes of sensitivity analysis for other secondary 
outcomes, including ulcer healing rate, QoL and markers of clinical success. 
Imputation methods will be fully documented in the SAP.  
7.4 DEVIATIONS FROM THE STATISTICAL ANALYSIS PLAN 
Any deviation(s) from the final statistical analysis plan in the final analysis will be 
described and justification given in the final report.  
 
7.5 HEALTH ECONOMIC ANALYSIS 
The economic evaluation will be based on both a modelling exercise and a patient 
level in-trial analysis. The main analyses will be performed from the perspective of 
the NHS and Personal Social Services. Secondary analyses will be performed from 
a societal perspective. The price year will be 2017-18. Discounting will be applied 
according to UK Government guidelines. The study will be reported according to 
current guidelines for economic evaluation (CHEERS).  
The within-trial analysis will compare early versus delayed endovenous treatment of 
superficial venous reflux in patients with chronic venous ulceration, within the time-
horizon of the extended trial. Data will be collected by case note review and 
questionnaires completed at baseline, 6 weeks, 6 months,12 months and at a single 
time point during October 2018 and March 2019. Resource use items in hospital and 
community care related to the treatment of venous ulceration, adverse events or 
complications will be recorded for each patient at each follow-up. Resource use will 
be multiplied by UK unit costs obtained from published literature, Healthcare 
Resource Groups (HRG) costs, and manufacturers’ list prices to calculate overall 
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costs. A standard tariff will be applied for each bandage change. Utilities (QALYs) 
will be calculated from the EQ-5D questionnaire administered to patients at each 
follow-up. The extent of missing data will be assessed and appropriate methods to 
handle missing data will be applied. The incremental cost-effectiveness ratio will be 
calculated and compared to current UK decision making thresholds. Sensitivity 
analysis will be carried out to test the robustness of results to alternative 
assumptions (for example, about missing data, or using per-protocol estimates of 
treatment effect) or alternative data (for example, about unit costs). Probabilistic 
sensitivity analysis will be carried out using bootstrapping. 
 
A decision model will also be constructed to take into account outcomes that might 
be expected to occur beyond the timeframe of the RCT (e.g. recurrence, healing), 
the results of other RCTs that have assessed early or delayed endovascular therapy 
for treating venous ulcers, or any relevant comparators that are not considered in the 
RCT (e.g. surgery, bandaging only). The health states used in the model will be 
based on the natural history of chronic venous ulcers, to be obtained from the trial, 
from the literature and from expert opinion. . The inputs for the model will be the 
transition rates for moving from one state to another, the relative risks for each 
treatment compared with usual care, and the costs and HRQOL associated with 
each health state. Use of secondary and primary care patient resource use and EQ-
5D responses associated with health states will be estimated mainly from the trial. 
Sensitivity analyses will be carried out to test the robustness of the model results to 
alternative assumptions and alternative data. Probabilistic sensitivity analysis will be 
carried out using Monte-Carlo simulation. 
 
7.6 LOSSES TO FOLLOW-UP AND PROTOCOL VIOLATIONS 
The primary assessment involves intention-to-treat analysis. Therefore, strenuous 
efforts will be made to ensure that only patients willing to undergo either immediate 
or delayed superficial venous ablation and compression bandaging are randomised. 
Monthly reports of protocol violations will be provided by local sites to the trial 
coordinators, who reserve the right to suspend or exclude sites in the event of wilful 
protocol violations. Similarly, efforts will be made to obtain complete follow-up for all 
randomised participants (irrespective of whether or not they underwent allocated 
treatment). For those participants unable or unwilling to attend follow-up 
appointments, home-visits or follow-up by community nurses may be considered. 
A high rate of protocol violation was seen in previous trials of venous ulceration 
(including the ESCHAR trial). This is likely to reflect the reluctance and apprehension 
of elderly patients to undergo surgical interventions involving general anaesthesia. 
The modern management of superficial venous disease involves a range of 
minimally invasive, endovenous modalities that can be performed using local or no 
anaesthesia. Procedures are performed on an outpatient basis and can be 
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completed in around 30 minutes. Published studies of endovenous interventions 
have demonstrated excellent patient satisfaction and few treatment refusals. Due to 
the published evidence and extensive personal experience among the research 
team, the rate of participation should be higher and rate of protocol violations lower 
than previous studies. 
 
The following will be recorded as protocol deviations: 
1) Patients randomised to multilayer compression / stockings plus early venous 
reflux ablation, who receive endovenous intervention more than two weeks 
from randomization. 
2) Patients who are non-compliant with compression bandaging, defined as use 
<75% of the prescribed duration. 
3) Patients randomised to compression bandaging alone who undergo 
endovenous ablation prior to verified healing. 
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8. ADVERSE EVENTS  
8.1 REPORTING PROCEDURES  
During the first 12 months all serious adverse events and all intervention-related 
adverse events should be reported. Any serious adverse events reported at the 
October 2018 to March 2019 follow-up time point should be reviewed the Principal 
Investigator to assess whether they are related to the treatment pathway  and only 
related events should be reported to the sponsor via INFORM. Depending on the 
nature of the event the reporting procedures below should be followed. Any 
questions concerning adverse event reporting should be directed to the Chief 
Investigator in the first instance.  
8.2 RELATED ADVERSE EVENTS 
Patients randomised to early venous intervention have the potential risks of 
treatment. Competent, experienced medical staff will perform all procedures and 
every effort will be made to prevent adverse effects. The adverse events listed below 
are expected to be related to the endovenous interventions used in the trial and 
should be reported. Please note this is not an exhaustive list, if you suspect an 
event is related to treatment please contact the Trials Unit. 
Systemic 
• allergic reaction req. local / no treatment  
• migraine 
• visual disturbance 
• fainting 
• Cough / chest tightness 
• Systemic infection 
• PE 
• TIA 
• Stroke 
Local 
• Bleeding requiring intervention 
• Blistering of skin 
• Pressure damage 
• Nerve damage 
• DVT 
• Hematoma 
• Patient reported parathesia 
• Pigmentation of skin 
• Superficial thrombophlebitis 
• New ulcer 
• Deterioration of ulcer 
• Wound infection 
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8.3 NON SERIOUS ADVERSE EVENTS 
All such events, which are judged by the local PI to be related to the interventions, 
whether expected or not, should be recorded in InForm 
8.4 SERIOUS ADVERSE EVENTS 
In addition to clinical assessments, patients will be contacted on a monthly basis by 
telephone for 12 months to identify any additional treatments, admissions or other 
complications related to their leg ulceration. Unrelated serious adverse events will 
also be recorded and reported in accordance with the Good Clinical Practice 
guidance up to 12 months. Serious adverse events (SAE) are defined as those 
adverse events that: result in death; are life-threatening; require in-patient 
hospitalisation or prolongation of existing hospitalisation; result in persistent or 
significant disability or incapacity; result in congenital anomaly or birth defect; are 
cancer; or are other important medical events in the opinion of the responsible 
investigator (i.e. not life threatening or resulting in hospitalisation, but may jeopardise 
the participant or require intervention to prevent one or more of the outcomes 
described previously). 
All SAEs reported by participants at (or between) each follow-up visit will be 
recorded by local researchers and entered into InForm within 24 hours of the 
researcher becoming aware of the event.  
All SAEs will be reported by the trial manager to the Sponsor and Chair of the Data 
Monitoring Committee. Related and unexpected SAEs will also be reported to the 
relevant Ethics Committee. 
In the event that InForm is not accessible notify the Trial Manager, Francine Heatley:  
Tel: 0203 311 7371 (Mon to Fri 09.00 – 17.00) 
Email: EVRAtrial@imperial.ac.uk 
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9. REGULATORY ISSUES  
9.1 ETHICS APPROVAL  
After approval from the Research Ethics Committee, the study must be submitted for 
Site Specific Assessment (SSA) at each participating NHS Trust. The Chief 
Investigator will require a copy of the Trust R&D approval letter before accepting 
participants into the study. The study will be conducted in accordance with the 
recommendations for physicians involved in research on human subjects adopted by 
the 18th World Medical Assembly, Helsinki 1964 and later revisions.  
 
9.2 CONSENT  
Consent to enter the study must be sought from each participant only after a full 
explanation has been given, an information leaflet offered and time allowed for 
consideration. Signed participant consent should be obtained. The right of the 
participant to refuse to participate without giving reasons must be respected. After 
the participant has entered the study the clinician remains free to give alternative 
treatment to that specified in the protocol at any stage if he/she feels it is in the 
participant’s best interest, but the reasons for doing so should be recorded. In these 
cases the participants remain within the study for the purposes of follow-up and data 
analysis. All participants are free to withdraw at any time from the protocol treatment 
without giving reasons and without prejudicing further treatment. Patients will not be 
specifically reconsented for the collection data in October 2018 as they already 
consented for the collection of longer term data at the outset. Patients will be asked, 
however at the telephone contact if they wish to continue in the study.  
 
9.3 CONFIDENTIALITY  
The Chief Investigator will preserve the confidentiality of participants taking part in 
the study and is registered under the Data Protection Act.  
 
9.4 INDEMNITY  
Imperial College London holds negligent harm and non-negligent harm insurance 
policies, which apply to this study. 
 
9.5 SPONSOR  
Imperial College London will act as the main Sponsor for this study. Delegated 
responsibilities will be assigned to the NHS trusts taking part in this study.  
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9.6 FUNDING  
This project is funded by the National Institute for Health Research HTA (project 
number 11/129/197).  
9.7 QUALITY ASSURANCE AND CONTROL 
The study may be subject to inspection and audit by Imperial College London under 
their remit as sponsor and other regulatory bodies to ensure adherence to GCP and 
the NHS Research Governance Framework for Health and Social Care (2nd edition). 
Quality Control will be performed according to the requirements of the Risk 
Assessment performed by ICTU. The study may be audited by a Quality Assurance 
representative of the Sponsor. All necessary data and documents will be made 
available for inspection. 
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10. STUDY MANAGEMENT 
The study will be coordinated by a trial manager based at ICTU reporting to the 
Clinical Coordinators (MG and RB) and the Chief Investigator (AD). The Clinical 
Coordinators will liaise with local principal investigators (L-PI) to ensure that the trial 
is conducted locally according to protocol and in an expeditious manner. The 
organisational structure and responsibilities are outlines below.  
10.1 PRINCIPAL INVESTIGATORS 
The chief investigator and clinical coordinators have overall responsibility for: 
 Design and conduct of the study 
 Preparation of the Protocol and subsequent revisions 
 Managing the Trial Coordinating Centre 
 Development of SOPs 
10.2 TRIAL STEERING COMMITTEE 
A Trial Steering Committee (TSC) will be established in line with HTA guidance, 
consisting of the chief Investigator, clinical coordinators, trial manager, trial 
statistician, patient representative, an independent chair and at least 1 other 
independent member will be formed and will meet on a 6-monthly basis to discuss 
trial progress. The TSC is responsible for: 
 Agreement of the final Protocol 
 Agreeing the Data Analysis Plan 
 Reviewing progress of the study and, if necessary, agreeing changes 
to the Protocol 
 Reviewing new studies that may be of relevance 
 Review and approval of study reports 
10.3 DATA MONITORING COMMITTEE 
The independent Data Monitoring Committee (DMC) will be established in line with 
HTA guidance will focus on the rights, safety and wellbeing of study participants. 
DMC responsibilities are: 
 Reviewing unblinded interim data according to the schedule agreed by 
all DMC members. 
 Advising the Steering Committee if, in their view, the randomised data 
provide evidence that may warrant early termination for either safety or 
efficacy. 
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10.4 TRIAL COORDINATING CENTRE 
The Trial Coordinating Centre (TCC) is responsible for the overall coordination of the 
Study, including: 
 Study planning and organisation of Steering Committee meetings 
 Agreement of each local recruitment plan 
 Contractual issues with local study sites 
 Ethics Committee applications 
 Design, implementation and maintenance of IT systems for the study 
 Auditing and monitoring of overall progress of the study 
 Clinical safety monitoring (including the reporting of all “related” SAEs 
to the Chair of the DMC and Ethics Committee) 
 Liaison with the Data Monitoring Committee and (where appropriate) 
with regulatory authorities and other outside agencies 
 Responding to technical and administrative queries from local study 
sites 
10.5 LOCAL STUDY SITES 
The local principal investigators (L-PI) and clinical staff at the local study sites are 
responsible for: 
 Obtaining local R&D and management approval (aided by the Trial 
Coordinating Centre) 
 Provision of adequate clinic space and the identification of potentially 
eligible participants 
 Conducting study procedures and follow-up according to study protocol 
 Dealing with routine enquiries from participants and their families 
 Obtaining appropriate information to confirm potential primary and 
secondary study endpoints 
 Attend annual EVRA Study Collaborator Meetings to discuss study 
progress 
 
11. DOCUMENT RETENTION 
Data will be stored for a minimum of 10 years following completion of this trialin 
accordance with the Imperial College JCRO Archiving Study Documents SOP. Data 
generated by this work will be processed in accordance with the Data Protection Act 
1998. 
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12. PUBLICATION POLICY  
The findings will be disseminated to General Practitioners, nursing staff, surgeons 
and other health care professionals at regular research and educational meetings 
organised at local, regional, national and international levels. All analyses will be 
performed in compliance with a predefined analysis plan. The chief investigator, 
clinical coordinators and trial coordinator will be responsible for drafting the main 
reports from the study. Draft copies of any manuscripts will be provided to local 
principal investigators at each local study site, TSC members and all other 
collaborators for review prior to publication. The results will be put forward for critical 
peer review with a view to publication in relevant medical and nursing journals. 
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Appendix 1: Summary of assessments and follow-up visits 
Time point Estimated 
duration 
(mins) 
Clinical 
evaluation
*
 
Telephone 
follow-up
** 
Wound 
review/photo 
/tracing*** 
Collection of 
further 
endovenous 
intervention / 
duplex report  
Venous 
duplex 
Randomisation  Consent  Health 
Questionnaires 
(EQ-5D, SF-36, 
AVVQ)  
Screening 
Visit 
45 X    X  X
a
  
Baseline 
Visit 
60-90 X     X***   X X
b
 X 
1 month  30  X       
6 weeks 60-90 X  X
?
***  X
c
   X 
2 months 30  X X
?
      
3 months 30  X X
?
      
4 months 30  X X
?
      
5 months 30  X X
?
      
6 months 30  X X
?
     X 
7 months 30  X X
?
      
8 months 30  X X
?
      
9 months 30  X X
?
      
10 months 30  X X
?
      
11 months 30  X X
?
      
12 months 30  X X
?
     X 
Extension 
follow-up 
Oct18 to 
Mar 19 
240 X
d
 X  X   X
e
 X 
*. Demographic details (age, sex, ethnicity), Pregnancy test for woman of child bearing potential. General clinical details (body mass index, ankle brachial pressure index – performed within previous 4 weeks, comorbidities, medication history). Ulcer details 
(duration, progression, previous ulcer history, size of current ulcer – using photography and planimetry). Details of venous disease (previous deep vein thrombosis, previous venous interventions, pattern of venous reflux on duplex) 
**. Ulcer healing assessment, compression type, AE assessment, Concomitant medications, health resource use. ***tracing only performed at baseline & 6 weeks 
a. Approached    b Taken     c. Only for those who have early endovenous treatment  d. review of clinical notes only  e. patients will not be reconsented as already consented for longer term follow-up at outset but will be asked if they wish to continue 
?dependant on whether the ulcer has healed photo will be taken at verification visit and taken weekly for 4 weeks, unless otherwise confirmed by the trial manager. Once the ulcer has healed the patient will still be followed up with monthly phone calls. 
Protocol – Summary of changes 
Version Date Approved by 
ethics 
List of changes 
1.0 19/06/2013 15/08/2013        N/A original protocol 
2.0 06/01/2014 29/01/2014 1. Addition of abbreviation table, the sponsor, IRAS and UKCRN numbers 
2. ‘randomized’ replaced with English spelling ‘randomised’ throughout the document 
3. Study setting (section 4.2, page 12) amended to clarify that additional centres may join the trial at a 
later date 
4. Definition of ulcer healing clarified (Page 13), ‘For the purposes of the trial healing will be defined as the 
complete re-epithelialisation of the ulcerated leg in the absence of a scab with no dressing required. 
Healing cannot be assumed if a scab present.’  
5. 4.3.2 Secondary outcome measures section amended to include ‘ulcer reoccurrence’.  
6. ‘Assessment of range of ankle movement’ removed from the baseline assessment section (Page 17) 
7. Section 5.4 amended to clarify that patients can be offered intervention in the standard care 
(compression arm) if their ulcer has not healed at 6 months. 
8. Statistics and Data Analysis (section 7, Page 20) amended to reference Imperial College JCRO Archiving 
Policy 
9. Statistics and Data Analysis’, sample size paragraph (section 7.1, Page 20) amended for clarity, planned 
analysis paragraph (section 7.2, Page 20) amended for clarity of per-protocol analyses.  
10. Statistics and Data Analysis’ section (Page 21).  Addition of sections 7.3 Missing, Unused and Spurious 
Data & 7.4 Deviations from the statistical analysis plan added 
11. Statistics and Data Analysis’ section. Interim analyses: role of the Data Monitoring Committee (Page 22) 
removed / simplified into Section 10.3 to refer to the DMC charter. Interim analyses are now fully 
described in section 7.2 and the role of the DMC in section 10.3.  
12. Amend all multilayer bandage compression to multilayer bandage compression / stockings 
13. Serious adverse event (section 8.2) amended to clarify that SAEs should be reported to the Trial 
Manager by entering the data into InForm within 24 hours of becoming aware of the event.  
14. Section also amended to confirm that all SAEs will be reported to the sponsor and DMC but only 
related, unexpected SAEs will be reported to the ethics committee.  
15. Serious adverse event (section 8.2) amended to list all the expected adverse reactions 
3.0 10/03/2014 24/03/2014 1. Section 3.1 (Page 10) amended to add ‘Patients will be referred to secondary care as part of the 
standard care pathway as per the July 2013 NICE Guidelines. To aid recruitment, selected Primary Care 
trusts not currently involved in the trial will be set-up as Patient Identification Centres (PIC sites) 
Protocol – Summary of changes 
displaying posters, leaflets and disseminating patient information sheets to patients.  Selected Primary 
Care trusts involved in follow-up of the trial (research sites) will also aid recruitment by displaying 
posters, leaflets and disseminating patient information sheets to patients. Patients will still need to be 
referred to the secondary care recruiting sites to be consented and randomised into the trial.’   
2. Section 4.2 Study Setting (Page 14) amended to add ‘As per section 3.1 Primary Care Trusts will be set-
up as either PIC sites or research sites aiding recruitment by displaying posters, leaflets and 
disseminating patient information sheets. Patients will still need to be referred to the secondary care 
recruiting sites to be consented and randomised into the trial. ‘  
3. Section 4.2 Study Setting (Page 14) amended to add the additional secondary care sites who will recruit 
into the study. 
4.0 16/03/2016 12/04/2016 1. 7.1 SAMPLE SIZE CALCULATION amended to state ‘to identify a difference in 24-week healing rates of 
15% between the two groups (60% vs 75%) with 90% power and allowing for 10% dropout the study 
will therefore require 416 subjects (208 in each arm, 254 healed leg ulcers in total).’ ‘To incorporate 
further allowances for protocol violations and unexpected dropouts, the target sample size will be 450 
patients.’ This was to correct the original sample size of 500 participants which was calculated in error 
to the correct value of 450. 
5.0 06/04/2017 24/05/2017 1. To incorporate the HTA funding extension to the trial to allow for the collection of longer term follow-
up during October 2018 and March 2019. 
2. Amendments to the health economics section to clarify some items which were unclear in the previous 
version, and updates the protocol to reflect new NIHR guidelines. 
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1. Introduction 
Chronic leg ulcers are open “sores” on the lower limbs situated between the ankles and knees, 
which fail to heal within 6 weeks. The underlying cause of leg ulceration in over 70% of 
cases is lower limb venous dysfunction, sometimes evident as varicose veins but often 
undetectable by visual examination alone. The estimated overall prevalence of active venous 
ulceration is as high as 1.5 to 1.8 per 1000 population, increasing to 3.8 per 1000 population 
in those over 40 years of age. As patients with venous ulceration usually suffer episodes of 
recurrence between periods when the ulcer remains healed, the number of patients with a 
high risk of ulceration may actually be 4-5 fold higher.  
Venous ulcers are characterised by protracted healing times. Despite some recent advances in 
the management of patients with venous ulcers, 24 week healing rates in published 
randomized trials are around 60-65%, and the true population healing rates are likely to be 
significantly lower. 
For over a century, the treatment of superficial venous reflux has involved operative ligation 
and surgical stripping of the vein and avulsion of bulging varicose veins. Until recent years, 
open surgery has been considered the definitive treatment option for superficial venous 
reflux. However, the operation usually requires general anaesthesia and patients often suffer 
discomfort, bruising and significant time off work in the post-operative period. In addition, 
long-term studies have also identified significant complications of open surgery. In response 
to this high complication rate and a growing patient desire for less invasive treatments, a 
range of novel, minimally invasive endovenous treatment options have been developed and 
have gained in popularity over the last decade. Non-randomized studies suggest that 
outcomes may be improved by treating underlying superficial reflux using the latest 
technologies, but there is no robust evidence to support early intervention. Therefore, we 
believe that there is a cogent argument for conducting this trial at this time. 
1.1 Study Objectives 
Primary Objective 
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To study the clinical and cost effectiveness of early endovenous treatment of superficial 
venous reflux in addition to standard care compared to standard care alone in patients with 
chronic venous ulceration.  
Secondary Objectives 
 To assess the ulcer free time to 1 year 
 To assess the technical success of endovenous interventions 
1.2 Study Population 
Patients with leg ulceration referred to secondary care as part of the standard care pathway.   
1.3 Study Design 
The EVRA ulcer trial is a pragmatic, multicentre randomized clinical trial with participants 
randomized 1:1 to either: 
‘Standard’ therapy consisting of multilayer elastic compression bandaging / stockings with 
deferred treatment of superficial reflux (usually once the ulcer has healed)  
Early endovenous treatment of superficial venous reflux (within 2 weeks) in addition to  
standard therapy 
1.4 Study Outcomes 
Primary Outcome 
The primary outcome measure will be time to ulcer healing (from date of randomization to 
date of healing). For the purposes of this study, ulcer healing is defined as complete re-
epithelialisation of all ulceration on the randomised (reference) leg in the absence of a scab 
(eschar) with no dressing required. 
Secondary Outcomes 
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 Ulcer Healing Rate: 24-week healing rate will be reported in addition to time to ulcer 
healing. 
 Ulcer reoccurrence / Ulcer Free Time: Will be calculated up to 1 year for each study 
arm.  
 Quality Of Life (QoL): Disease specific (AVVQ) and generic (EQ5D & SF36) quality 
of life assessments will be compared at 6 weeks post randomisation, 6 months and 12 
months.  
 Health Economic Assessment 
 Other Markers of Clinical Success: The Venous Clinical Severity Score (VCSS) and 
will be assessed at 6 weeks. In addition, the incidence of complications related to the 
endovenous intervention as well as the presence of residual / recurrent varicose veins 
will also be assessed at 6 weeks. 
1.5 Study Sample Size 
The sample size calculation for this study was based on the primary outcome of ulcer healing. 
According to previous published literature, the 24-week healing rate in patients randomised 
to standard treatment (compression alone) was approximately 60%, while the 24-week 
healing rate of early treatment of superficial venous reflux may be as high as 82%1,2. 
In order to calculate a sample size for this study, we estimate a benefit associated with early 
treatment of around 15%. To identify a difference in 24-week healing rates of 15% between 
the two groups (60% vs 75%) with 90% power and allowing for 10% dropout, the study will 
therefore require 416 subjects (208 per group).  
1.6 Randomisation 
The normal clinical team will make initial contact with potentially eligible patients at the 
referral visit. 
Those who consent will be registered on the InForm ITM (Integrated Trial Management) 
System, a web-based data entry system, which is maintained by ICTU, and their eligibility 
for the study confirmed. A randomization list will be loaded onto the InForm system for each 
centre (as stratification will be by centre) before recruitment commences, having been 
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prepared in advance by a statistician who is independent of the study. Each potential 
participant, if confirmed to be eligible, will be assigned the next available entry in the 
appropriate randomization list (i.e. without foreknowledge). Thereafter, treatment allocation 
will not be blinded (with the exception of assessment of ulcer healing). For patients with 
bilateral venous ulceration, the worst leg (according to the patient) will be designated the 
‘reference leg’. Interventions may be performed on both legs, if deemed appropriate by the 
responsible clinician. 
1.7 Schedule of Time 
The study started on 24th October 2013 and is expected to recruit for about two years and 
follow up for another year after the recruitment of last patient. The overall study timetable is 
summarised in Figure 1. The independent Data Monitoring Committee (DMC) meeting will 
be scheduled yearly with a Chairman’s review every 6 months.  
 
Figure 1 EVRA study Gantt chart 
2. General Considerations 
2.1 Analysis Strategy 
All the primary analyses will be on an intention-to-treat basis. Histograms and boxplots will 
be used to check the distribution and possible outliers for continuous variables. Mathematical 
transformations will be applied, where appropriate, in order to render the continuous 
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variables distribution normally distributed. Continuous variables that follow an 
approximately normal distribution will be summarised using means and standard deviations. 
Skewed continuous variables will be summarised using medians and inter-quartile ranges. 
Categorical variables will be summarised using frequencies and percentages.  
The primary outcome will be time to complete healing and we will test the hypothesis that 
there is no difference in this between the control and intervention groups using a log-rank test 
with stratification by study centre (two-tailed, 5% significance level). Kaplan-Meier survival 
curves will also be presented and as a subsidiary analysis we will investigate the effect of 
participant age, ulcer size at baseline and chronicity on time to complete healing using Cox 
regression with centre included in the model as random effect to adjust for potential centre 
effect. 
For the secondary outcome of ulcer free time, multiple regression will be used adjusting for the 
above covariates.  
The quality of life (QoL) data will be summarised across baseline, 6-week, 6-month and 12-
month after randomisation for both arms by means and 95% confidence intervals (CI) or 
median and inter quartiles, depending on the distribution of the data.  
Health economic assessment will be carried by the trial health economist and thus will not be 
included in this statistical analysis plan.  
2.2 Definition of Population for Analysis 
The study population will comprise all participants who were randomised.  
2.3 Data Management 
Data is collected and managed using InForm: an electronic data capture system built around 
an Oracle database. The InForm system includes validation rules for data entry to help ensure 
data accuracy, and has a full audit trial of data entry and changes. Data queries will be raised 
for inconsistent, impossible or missing data.  
2.4 Missing Data 
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There will be no data imputation for missing data in the primary endpoint (time to healing) and 
the secondary endpoints of 24-week healing rate and ulcer free time. However, the level and 
pattern of the missing data in the baseline variables and outcomes will be reported. The 
potential causes of any missingness will be investigated and documented as far as possible.  
Any missing data will be dealt with using methods appropriate to the conjectured missingness 
mechanism and level of missingness.  
2.5 Level of Significance 
The primary outcome and secondary outcomes will be tested using a two-tailed hypothesis 
test with a 5% significance level. For secondary outcomes, there will be no adjustment for 
multiple testing.  
2.6 Losses to Follow-up and Withdrawals 
All the primary analyses will be performed on an intention-to-treat basis. Only patients 
willing to undergo either immediate or delayed superficial venous ablation with compression 
bandaging are randomised. All randomised participants will be followed-up for one year 
(irrespective of whether or not they underwent allocated treatment). For those participants 
unable or unwilling to attend follow-up appointments, home-visits or follow-up by 
community nurses may be considered. 
Subjects who die, withdraw from the study, or are lost to follow-up before ulcer healing will 
be censored in the Kaplan Meier and Cox regression analyses at last follow-up visit.  
2.7 Protocol Violations 
A high rate of protocol violations was seen in previous trials of venous ulceration (including 
the ESCHAR trial) and this is likely to reflect the reluctance and apprehension of elderly 
patients to undergo surgical interventions involving general anaesthesia. The treatment of 
superficial venous disease involves a range of minimally invasive, endovenous modalities 
that can be performed using local or no anaesthesia. Procedures are performed on an 
outpatient basis and can be completed in around 30 minutes. Published studies of endovenous 
interventions have demonstrated excellent patient satisfaction and few treatment refusals. 
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Due to the published evidence and extensive personal experience among the research team, 
we believe that the rate of participation will be higher and rate of protocol violations will be 
lower than previous studies. 
The following will be recorded as protocol deviations: 
1) Patients randomised to multilayer compression / stockings plus early venous reflux 
ablation, who receive endovenous intervention more than two weeks from randomization. 
2) Patients who are non-compliant with compression bandaging, defined as use <75% of the 
prescribed duration. 
3) Patients randomised to compression bandaging alone who undergo endovenous ablation 
prior to verified healing. 
The type and reason of protocol violation will be documented in this study, and the summary 
of protocol violations will be reported in both arms.    
2.8  Deviations from the SAP 
All deviations from the SAP will be disclosed in the final analysis report. If problems or 
fundamental issues become apparent in the on-going checking that forms part of the 
statistical analysis, the trial statistician will raise these with a senior statistician who will 
consult with the appropriate individuals. Any such action and subsequent decisions will be 
documented in the final statistical analysis report.  
3. Interim Analysis 
No formal interim analyses are planned. Informal interim analyses will be performed if requested 
by the Data Monitoring Committee (DMC) but findings will be made available to members of the 
DMC only. Unless advised by the DMC in response to clear evidence of benefit or hazard, the 
Steering Committee, collaborators, participants and all study staff (except those who provide 
the confidential analyses to the DMC) will remain blind to the results until the end of the 
study. 
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4. Analysis Plan  
4.1 Recruitment Details 
Details about patient enrolment, follow-up and inclusion in analysis will be provided using a 
consort diagram (Figure 1).  
Recruitment will be summarised by a breakdown of the reasons for exclusion in tabular form. 
4.2 Baseline Characteristics 
Baseline characteristics, including demographics, medical history, ulcer history, and details 
of current ulcers will be summarised by treatment group using appropriate descriptive 
statistics for all randomised participants defined in 2.2 (Table 1, Table 2, Table 3 and Table 
4).   
4.3 Primary Endpoints 
The primary outcome will be time to complete healing and we will test the hypothesis that 
there is no difference in this between the control and intervention groups using a log-rank test 
with stratification by study centres. Kaplan-Meier survival curves will also be presented. We 
will investigate the effect of the study intervention on time to complete healing after adjusting 
for potential confounders listed in section 2.1 using Cox regression. To adjust for potential 
centre effect, centre will be included in the Cox regression analysis as random effect (Table 
9). 
4.4 Ulcer Free Time to 1 year and 24-week Ulcer Healing Rate  
Table 5 summarises the ulcer free time to 1 year and 24-week ulcer healing rate between the 
two arms. In the case that a patient is dead, withdrawn or lost to follow-up before 1 year, 
ulcer free time will be calculated as the time from randomisation until last follow-up. We will 
investigate the effect of the study intervention on ulcer free time after adjusting for potential 
confounders (Table 9) using multiple linear regression (if the assumption of normality can be 
met). If the assumption of normality cannot be met (there is no suitable transformation), ulcer 
free time will be categorized and analysed using appropriate regression methods to adjust for 
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potential confounders. The 24-week healing rate and associated 95% confidence interval will 
be obtained from the Kaplan-Meier analysis (4.3). 
4.5 Quality of Life 
The quality of life questionnaires include disease specific (AVVQ) and generic (EQ5D & SF-
36) components. AVVQ will be recoded according to its manual3. The SF-36 will be scored 
using Health Outcome Scoring Software 4.0  for the physical health and mental health 
dimensions, and all eight scales, including physical functioning, role limitations due to 
physical health, role limitations due to emotional problems, energy/fatigue, emotional well-
being, social functioning, pain, and general health. The index-based values (‘utilities’) will be 
calculated by the EQ-5D-5L Crosswalk Index Value Calculator downloaded from the EQ-5D 
official website.  
The QoL scores will be presented using line plots for each study arm to illustrate trends in 
AVVQ score, SF-36 and EQ-5D-5L over time. Depending on the distribution of the data, the 
means and 95% CI of means or medians and inter-quartiles at each time point, including 
baseline, 6-week, 6-month and 12-month after randomisation, will be reported.   
4.6 Markers for Clinical Success 
Clinical success will be assessed using the Venous Clinical Severity Score (VCSS), which is 
measured at baseline and 6 weeks post-randomisation. The change in clinical classification in 
the Clinical, Etiologic, Anatomic, Pathophysiological (CEAP) score at 6 weeks post-
randomization from baseline will be reported and the chi-square test will be used to compare 
between the two arms. Similarly, change in VCSS score will be compared between the two 
arms using the t-test (assuming change in VCSS is normally distributed) or appropriate non-
parametric test (if change in VCSS is not normally distributed).  
Table 6 shows the proportions of patients with downgrade of clinical classification from C6 
to C5 at 6-weeks post-randomisation and VCSS score. The VCSS scores at 6 weeks post-
randomization and baseline will be summarised using boxplot for both arms.  
4.7 Safety Data 
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The safety data, including adverse events (AEs) and serious adverse events (SAEs) will be 
provided in a tabular format for the two arms (Table 7 and Table 8). AEs will be summarised by 
description and outcome and SAEs will be summarised by SAE reason, frequency, severity, and 
relationship to treatment, outcome and expectedness.  
4.8 Derived Variables 
1. Deep vein reflux is defined as iliac, femoral, popliteal or crural deep vein reflux 
detected by Duplex scan. 
2. Deep vein obstruction is defined as iliac, femoral, popliteal or crural deep vein 
outflow obstruction detected by Duplex scan. 
3. Time to ulcer healing will be calculated as the difference between the final healing 
date and date of randomisation. Final healing date is collected in the InForm database 
and this variable is entered by trial manager after experts agree on the healing date. 
Patients will be censored at the time of last follow-up if they are dead, withdrawn or 
lost to follow-up before primary ulcer healing. The follow-up time is one year after 
randomisation and thus patients with unhealed primary ulcer at one year after 
randomisation will be also censored.   
4. One-year ulcer free time will be calculated as total follow-up time in days (i.e. one 
year or time to the last follow-up if patients are dead, withdrawn or lost to follow 
before one year) deducting the total duration of ulcers, including primary ulcer and  
recurrences.  
5. Ulcer chronicity will be calculated as the difference between the date of current ulcer 
appeared and the date of randomisation.  
5. Sensitivity analysis 
As a sensitivity analysis, we will perform a per-protocol analysis by excluding patients with 
protocol violations. This sensitivity analysis will cover all primary and secondary outcomes. 
The surgeon data is collected separately and not included in the InForm database. If the 
surgeon data can be merged into the main database and, we will carry out another sensitivity 
analysis by including surgeon as a random effect in the Cox regression ana lysis for primary 
outcome.   
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Tables 
Table 1 Baseline characteristics between the EVRA and standard treatment group* 
 EVRA Standard 
 N= N= 
Age   
Height   
Weight   
BMI   
Gender   
Male   
Female   
Smoking   
Never   
Former   
Current   
Ethnicity   
White   
Mixed   
Asian   
Black   
Chinese   
Other   
EQ-5D   
Mobility   
Self-care   
Usual activities   
Pain/discomfort   
Anxiety/depression   
Health state score   
SF-36   
Physical function   
Role-Physical   
Body pain   
General Health   
Vitality   
Social Functioning   
Role-Emotional   
Mental Health   
Total AVVQ    
*
 Data presented as frequency (percentage) for categorical variables and mean (SD) for continuous 
variables 
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Table 2 Summary of medical history & concurrent medication* 
 EVRA Standard 
 N= N= 
Previous pregnancy†   
Yes   
History of DVT in 
pregnancy (yes) 
  
No   
Hormone therapy†   
None   
Previous HRT   
Current HRT   
Previous OC   
Current OC   
Previous Rheumatoid 
disease (yes) 
  
Previous DVT   
Current antiplatelet therapy   
None   
Aspirin   
Clopidogrel   
Other   
Current anticoagulation 
therapy 
  
None   
Warfarin   
New oral anticoagulants   
Other   
Current Steroids   
Yes   
No   
Current Trental 
(pentoxyfilne) 
  
Yes   
No   
Diabetes   
Yes   
No   
* 
Data presented as frequency (percentage) for categorical variables 
† 
Female only
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Table 3 Summary of ulcer history* 
 EVRA Standard 
 N= N= 
Previous ulcer (yes)   
Ulcer dressing   
NA   
Inadine   
Other   
Baseline Compression   
None   
KTwo   
Three-layer bandage   
Four-layer bandage   
European short stretch   
Stocking   
Other   
Time of wearing   
Day & night   
Day only   
* 
Data presented as frequency (percentage) for categorical variables 
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Table 4 Characteristics of current ulcer* 
 EVRA Standard 
 N= N= 
Time since ulcer diagnosis   
Trial ulcer leg   
Right   
Left   
Ulcer location   
Lateral   
Medial   
Circumferential   
Ulcer size (cm2)   
Duplex Scan: Deep Vein   
Normal   
Abnormal†   
Reflux   
Outflow obstruction   
CEAP Score   
Clinical signs – grade   
C5   
C6   
Clinical signs – presentation   
Asymptomatic   
Symptomatic   
Etiologic classification   
Primary   
Secondary   
Deep   
No venous cause   
Anatomic distribution   
Superficial   
Perforator   
Deep   
Pathophysiologic 
dysfunction 
  
Reflux   
Obstruction   
Both   
No venous cause   
VCSS Score   
Palpable pedal pulses   
Yes   
No   
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*
 Data presented as frequency (percentage) for categorical variables and median (range) for 
continuous variables 
†
A patient can have both deep vein reflux and obstruction   
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Table 5 Summary of 24-week ulcer healing rate and ulcer free time* 
 EVRA Standard 
N= N= 
24-week ulcer healing rate   
No. of patients with recurrent 
ulcer 
  
Ulcer free time   
* Data presented as frequency (percentage) for categorical variables and median (range) for 
continuous variables 
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Table 6 Summary of clinical success at 6 weeks after randomisation 
 EVRA Standard 
P 
 N= N= 
VCSS total score    
Clinical classification downgrade from C6 to C5 
Yes    
No   
    
*
 Data presented as frequency (percentage) for categorical variables   
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Table 7 Summary of adverse events 
 EVRA Standard 
 N= N= 
No. surgical procedures   
Total number of AEs    
Description of AE   
Systemic   
Local   
Outcome   
Recovered   
Not yet recovered   
Death   
Unknown   
Missing   
*
 Data presented as frequency (percentage) for categorical variables   
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Table 8 Summary of serious adverse events 
 EVRA Standard 
 N= N= 
No. surgical procedures   
Total number of SAEs    
Serious reason   
Death   
Life threatening   
Persistently disabling   
Hospitalisation required   
Congenital abnormality   
Other   
Frequency   
Single Episode   
Intermittent   
Frequent   
Continuous   
Unknown   
Severity   
Mild   
Moderate   
Severe   
Life threatening or 
disabling 
  
Relation to procedure   
Not related   
Unlikely   
Possible   
Probable   
Definite   
Outcome   
Recovered   
Not yet recovered   
Death   
Unknown   
Expectedness   
Expected   
Unexpected   
*
 Data presented as frequency (percentage) for categorical variables 
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Table 9 Summary of the results 
 Univariate model* Multivariate model† 
 Effect of EVAR 
compared to Standard 
P value 
Effect of EVAR 
compared to Standard 
P value 
Time to ulcer 
healing 
    
Ulcer free time     
*
 Adjusted by centre (centre included in the model as a random effect) 
†
 Adjusted by centre, age, ulcer size and chronicity (centre included in the model as random effect and 
age, ulcer size and chronicity as fixed effects).  
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Figure 1 CONSORT diagram of the study population 
Figure 2 Kaplan-Meier curve showing ulcer healing time in the EVRA and standard 
(delayed) arm  
Figure 3 Time trend of EQ5D: a) Health Score; b) Index Value in the two arms 
Figure 4 Time trend of SF-36 in the two arms 
Figure 5 Time trend of AVVQ in the two arms  
Figure 6 Summary of clinical success: change in VCSS between baseline and 6 weeks 
after randomisation 
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1. Introduction 
Chronic leg ulcers are open “sores” on the lower limbs situated between the ankles and knees, 
which fail to heal within 6 weeks. The underlying cause of leg ulceration in over 70% of cases 
is lower limb venous dysfunction, sometimes evident as varicose veins but often undetectable 
by visual examination alone. The estimated overall prevalence of active venous ulceration is 
as high as 1.5 to 1.8 per 1000 population, increasing to 3.8 per 1000 population in those over 
40 years of age. As patients with venous ulceration usually suffer episodes of recurrence 
between periods when the ulcer remains healed, the number of patients with a high risk of 
ulceration may actually be 4-5 fold higher.  
Venous ulcers are characterised by protracted healing times. Despite some recent advances in 
the management of patients with venous ulcers, 24 week healing rates in published randomized 
trials are around 60-65%, and the true population healing rates are likely to be significantly 
lower. 
For over a century, the treatment of superficial venous reflux has involved operative ligation 
and surgical stripping of the vein and avulsion of bulging varicose veins. Until recent years, 
open surgery has been considered the definitive treatment option for superficial venous reflux. 
However, the operation usually requires general anaesthesia and patients often suffer 
discomfort, bruising and significant time off work in the post-operative period. In addition, 
long-term studies have also identified significant complications of open surgery. In response 
to this high complication rate and a growing patient desire for less invasive treatments, a range 
of novel, minimally invasive endovenous treatment options have been developed and have 
gained in popularity over the last decade. Non-randomized studies suggest that outcomes may 
be improved by treating underlying superficial reflux using the latest technologies, but there is 
no robust evidence to support early intervention. Therefore, we believe that there is a cogent 
argument for conducting this trial at this time. 
1.1 Study Objectives 
Primary Objective 
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To study the clinical and cost effectiveness of early endovenous treatment of superficial venous 
reflux in addition to standard care compared to standard care alone in patients with chronic 
venous ulceration.  
Secondary Objectives 
 To assess the ulcer free time to 1 year 
 To assess the technical success of endovenous interventions 
1.2 Study Population 
Patients with leg ulceration referred to secondary care as part of the standard care pathway.   
1.3 Study Design 
The EVRA ulcer trial is a pragmatic, multicentre randomized clinical trial with participants 
randomized 1:1 to either: 
‘Standard’ therapy consisting of multilayer elastic compression bandaging / stockings with 
deferred treatment of superficial reflux (usually once the ulcer has healed)  
Early endovenous treatment of superficial venous reflux (within 2 weeks) in addition to 
standard therapy 
1.4 Study Outcomes 
Primary Outcome 
The primary outcome measure will be time to ulcer healing (from date of randomization to date 
of healing). For the purposes of this study, ulcer healing is defined as complete re-
epithelialisation of all ulceration on the randomised (reference) leg in the absence of a scab 
(eschar) with no dressing required. 
Secondary Outcomes 
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 Ulcer Healing Rate: 24-week healing rate will be reported in addition to time to ulcer 
healing. 
 Ulcer reoccurrence / Ulcer Free Time: Will be calculated up to 1 year for each study 
arm.  
 Quality Of Life (QoL): Disease specific (AVVQ) and generic (EQ5D & SF36) quality 
of life assessments will be compared at 6 weeks post randomisation, 6 months and 12 
months.  
 Health Economic Assessment 
 Other Markers of Clinical Success: The Venous Clinical Severity Score (VCSS) and 
will be assessed at 6 weeks. In addition, the incidence of complications related to the 
endovenous intervention as well as the presence of residual / recurrent varicose veins 
will also be assessed at 6 weeks. 
1.5 Study Sample Size 
The sample size calculation for this study was based on the primary outcome of ulcer healing. 
According to previous published literature, the 24-week healing rate in patients randomised to 
standard treatment (compression alone) was approximately 60%, while the 24-week healing 
rate of early treatment of superficial venous reflux may be as high as 82%1,2. 
In order to calculate a sample size for this study, we estimate a benefit associated with early 
treatment of around 15%. To identify a difference in 24-week healing rates of 15% between 
the two groups (60% vs 75%) with 90% power and allowing for 10% dropout, the study will 
therefore require 416 subjects (208 per group).  
1.6 Randomisation 
The normal clinical team will make initial contact with potentially eligible patients at the 
referral visit. 
Those who consent will be registered on the InForm ITM (Integrated Trial Management) 
System, a web-based data entry system, which is maintained by ICTU, and their eligibility for 
the study confirmed. A randomization list will be loaded onto the InForm system for each 
centre (as stratification will be by centre) before recruitment commences, having been prepared 
 
 
EVRA Final Statistical Analysis Plan_v4 Page 7 of 31 
in advance by a statistician who is independent of the study. Each potential participant, if 
confirmed to be eligible, will be assigned the next available entry in the appropriate 
randomization list (i.e. without foreknowledge). Thereafter, treatment allocation will not be 
blinded (with the exception of assessment of ulcer healing). For patients with bilateral venous 
ulceration, the worst leg (according to the patient) will be designated the ‘reference leg’. 
Interventions may be performed on both legs, if deemed appropriate by the responsible 
clinician. 
1.7 Schedule of Time 
The study started on 24th October 2013 and is expected to recruit for about two years and follow 
up for another year after the recruitment of last patient. The overall study timetable is 
summarised in Figure 1. The independent Data Monitoring Committee (DMC) meeting will be 
scheduled yearly with a Chairman’s review every 6 months.  
 
Figure 1 EVRA study Gantt chart 
2. General Considerations 
2.1 Analysis Strategy 
All the primary analyses will be on an intention-to-treat basis. Histograms and boxplots will be 
used to check the distribution and possible outliers for continuous variables. Mathematical 
transformations will be applied, where appropriate, in order to render the continuous variables 
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distribution normally distributed. Continuous variables that follow an approximately normal 
distribution will be summarised using means and standard deviations. Skewed continuous 
variables will be summarised using medians and inter-quartile ranges. Categorical variables 
will be summarised using frequencies and percentages.  
The primary outcome is time to complete healing and we will test the hypothesis that there is 
no difference in this between the control and intervention groups using a Cox model with study 
centre as a random effect. Kaplan-Meier survival curves will also be presented. As a subsidiary 
analysis we will investigate the effect of potential confounders (age, ulcer chronicity and ulcer 
size) on the treatment effect and time to complete healing using Cox regression, again with 
centre included in the Cox regression analysis as random effect (Table 9).  
For the secondary outcome of ulcer free time, multiple regression (ordinal, if not normally 
distributed) will be used to adjust for the above covariates.  
The quality of life (QoL) data will be summarised across baseline, 6-week, 6-month and 12-
month after randomisation for both arms by means and 95% confidence intervals (CI) or 
median and inter quartiles, depending on the distribution of the data.  
Health economic assessment will be carried by the trial health economist and thus will not be 
included in this statistical analysis plan.  
2.2 Definition of Population for Analysis 
The study population will comprise all participants who were randomised. A secondary per-
protocol analysis will also be carried out after excluding patients with protocol violations. For 
the analysis of ulcer free time, the population for analysis will be patients with complete follow-
up data only. This is because ulcer free time to one year depends on the time of primary ulcer 
healing and duration of recurrent ulcer (for example, patients with ulcer free time of 0 day may 
have an unhealed primary ulcer at 1 year follow-up, or may have withdrawn from the study 
after healing at month 1, or may have withdrawn from the study after healing at month 11). By 
adding this constraint some bias may have been introduced (as the analysis will have been 
based on complete cases only) but ulcer free time will have only one interpretation. As a 
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sensitivity analysis, the analysis of ulcer free time will therefore be repeated using all the 
patients, irrespective of length of follow up. This should give a very conservative estimate of 
the treatment effect. 
2.3 Data Management 
Data is collected and managed using InForm: an electronic data capture system built around an 
Oracle database. The InForm system includes validation rules for data entry to help ensure data 
accuracy, and has a full audit trial of data entry and changes. Data queries will be raised for 
inconsistent, impossible or missing data.  
2.4 Missing Data 
There will be no data imputation for missing data in the primary endpoint (time to healing) and 
the secondary endpoints of 24-week healing rate and ulcer free time. However, the level and 
pattern of the missing data in the baseline variables and outcomes will be reported. The 
potential causes of any missingness will be investigated and documented as far as possible.  
Any missing data will be dealt with using methods appropriate to the conjectured missingness 
mechanism and level of missingness.  
2.5 Level of Significance 
The primary outcome and secondary outcomes will be tested using a two-tailed hypothesis test 
with a 5% significance level. For secondary outcomes, there will be no adjustment for multiple 
testing.  
2.6 Losses to Follow-up and Withdrawals 
All the primary analyses will be performed on an intention-to-treat basis. Only patients willing 
to undergo either immediate or delayed superficial venous ablation with compression 
bandaging are randomised. All randomised participants will be followed-up for one year 
(irrespective of whether or not they underwent allocated treatment). For those participants 
unable or unwilling to attend follow-up appointments, home-visits or follow-up by community 
nurses may be considered. 
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Subjects who die, withdraw from the study, or are lost to follow-up before ulcer healing will 
be censored in the Kaplan Meier and Cox regression analyses at last follow-up visit.  
2.7 Protocol Violations 
A high rate of protocol violations was seen in previous trials of venous ulceration (including 
the ESCHAR trial) and this is likely to reflect the reluctance and apprehension of elderly 
patients to undergo surgical interventions involving general anaesthesia. The treatment of 
superficial venous disease involves a range of minimally invasive, endovenous modalities that 
can be performed using local or no anaesthesia. Procedures are performed on an outpatient 
basis and can be completed in around 30 minutes. Published studies of endovenous 
interventions have demonstrated excellent patient satisfaction and few treatment refusals. Due 
to the published evidence and extensive personal experience among the research team, we 
believe that the rate of participation will be higher and rate of protocol violations will be lower 
than previous studies. 
The following will be recorded as protocol deviations: 
1) Patients randomised to multilayer compression / stockings plus early venous reflux ablation, 
who receive endovenous intervention more than two weeks from randomization. 
2) Patients who are non-compliant with compression bandaging, defined as use <75% of the 
prescribed duration. 
3) Patients randomised to compression bandaging alone who undergo endovenous ablation 
prior to verified healing. 
The type and reason of protocol violation will be documented in this study, and the summary 
of protocol violations will be reported in both arms.    
2.8  Deviations from the SAP 
All deviations from the SAP will be disclosed in the final analysis report. If problems or 
fundamental issues become apparent in the on-going checking that forms part of the statistical 
analysis, the trial statistician will raise these with a senior statistician who will consult with the 
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appropriate individuals. Any such action and subsequent decisions will be documented in the 
final statistical analysis report.  
3. Interim Analysis 
No formal interim analyses are planned. Informal interim analyses will be performed if requested 
by the Data Monitoring Committee (DMC) but findings will be made available to members of the 
DMC only. Unless advised by the DMC in response to clear evidence of benefit or hazard, the 
Steering Committee, collaborators, participants and all study staff (except those who provide 
the confidential analyses to the DMC) will remain blind to the results until the end of the study. 
4. Analysis Plan  
4.1 Recruitment Details 
Details about patient enrolment, follow-up and inclusion in analysis will be provided using a 
consort diagram (Figure 2).  
Recruitment will be summarised by a breakdown of the reasons for exclusion in tabular form. 
4.2 Baseline Characteristics 
Baseline characteristics, including demographics, medical history, ulcer history, and details of 
current ulcers will be summarised by treatment group using appropriate descriptive statistics 
for all randomised participants defined in 2.2 (Table 1, Table 2, Table 3 and Table 4).  
4.3 Treatment Summary 
Type of endovenous treatment received (Endothermal alone, Foam sclerotherapy alone, 
Mechanochemical alone (MOCA), Endothermal plus Foam, or MOCA plus Foam) will be 
summarised by treatment group using appropriate descriptive statistics for all randomised 
participants defined in 2.2 (Table 5).  
4.4 Primary Endpoints 
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The primary outcome is time to complete healing and we will test the hypothesis that there is 
no difference in this between the control and intervention groups using a Cox model with study 
centre as a random effect (Table 6). Kaplan-Meier survival curves and the log-ran test will also 
be presented (Figure 3). As a subsidiary analysis we will investigate the effect of potential 
confounders listed in section 2.1 (age, ulcer chronicity and ulcer size) on the treatment effect 
and on time to complete healing using Cox regression, again with centre included in the Cox 
regression analysis as random effect (Table 6). To assess whether the treatment effect is 
consistent across all patient sub-groups, the hazard ratios and 95% confidence intervals for 
treatment from the above Cox regression models (with adjustment for potential confounders 
and centre as a random effect) will be re-calculated for each of the following subgroups 
separately; BMI (<23, 23.0-25.0, 25.01-30.0, > 30), Age (≤49, 50-69, 70+), gender (male, 
female), smoking (Never, previous, current), ulcer size (by quartile), ulcer duration (by 
quartile), history of deep vein thrombosis (yes, no), history of rheumatoid arthritis (yes, no), 
taking anti-platelet therapy (yes, no), history of intervention on previous leg ulcer (yes, no 
intervention, no previous ulcer) and baseline EQ5D (by quartile). The results will be presented 
using a Forest plot (Figure 4), with the overall result also included at the bottom. We will also 
use Cox regression to look for differences between the treatment arms by type of endovenous 
treatment (Endothermal alone, Foam sclerotherapy alone, Mechanochemical alone (MOCA), 
Endothermal plus Foam, or MOCA plus Foam). Results (hazard ratios and 95% confidence 
intervals will also be presented graphically in the Forest plot (Figure 5). These subsidiary 
analyses are intended to provide reassurance that the observed treatment effect is consistent 
across all patient sub-groups. The study is not powered to detect differences between sub-
groups and any observed patterns should be interpreted extremely cautiously, owing to the 
smaller numbers and increased chance of Type I error. For Cox regression models the 
proportionality assumption will be assessed graphically (using diagnostic plots) and using 
Grambsch and Therneau tests and overall fit will be assessed graphically by plotting the 
Nelson-Aalen cumulative hazard function versus the Cox-Snell residuals and comparing to a 
45° reference line. 
4.5 Ulcer Free Time to 1 year and 24-week Ulcer Healing Rate  
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Table 7 summarises the ulcer free time to 1 year and 24-week ulcer healing rate between the 
two arms. In the case that a patient is dead, withdrawn or lost to follow-up before 1 year, ulcer 
free time will be calculated as the time from randomisation until last follow-up. Multiple linear 
regression will be used to assess the difference between the treatments arms, with centre as a 
random effect, before and after adjustment for age, ulcer size and ulcer chronicity (Table 8). 
Graphical methods will be used to assess whether the assumption of normality is met. If the 
assumption of normality is not met, and there is no suitable transformation, ulcer free time will 
be categorized (by quartiles) and the analysis will instead be performed using ordinal 
regression. Model fit will be assessed using residual plots and/or goodness-of-fit tests, as 
appropriate. The 24-week healing rate and associated 95% confidence interval will be obtained 
from the Kaplan-Meier analysis (4.3). The primary analysis will be based on study participants 
with at least 1 year of follow up only (as explained in 2.2). As a sensitivity analysis we will 
repeat the above regression model (adjusted for age, ulcer size and ulcer chronicity, and centre) 
using all the study participants, irrespective of length of follow up.  
To assess whether the treatment effect on ulcer free time is the same across all patient sub-
groups, the coefficients and 95% confidence intervals for the treatment effect from the above 
multiple linear (or ordinal) regression model (based on study participants with follow up of at 
least 1 year) will be re-calculated for each of the following subgroups separately; BMI (<23, 
23.0-25.0, 25.01-30.0, > 30), age (≤49, 50-69, 70+), gender (male, female), smoking (Never, 
previous, current), ulcer size (by quartile), ulcer duration (by quartile), history of deep vein 
thrombosis (yes, no), history of rheumatoid arthritis (yes, no), taking anti-platelet therapy (yes, 
no), history of intervention on previous leg ulcer (yes, no intervention, no previous ulcer) and 
baseline EQ5D (by quartile). The results of this subgroup analysis will be presented in a Forest 
plot with the overall result also included at the bottom (Figure 6). Differences between the 
treatment arms by type of endovenous treatment (Endothermal alone, Foam sclerotherapy 
alone, Mechanochemical alone (MOCA), Endothermal plus Foam, or MOCA plus Foam) will 
also be investigated and the results (model coefficients and 95% confidence intervals) will be 
presented graphically in the Forest plot (Figure 7). These subsidiary analyses are intended to 
provide reassurance that the observed treatment effect is consistent across all patient sub-
groups. The study is not powered to detect differences between sub-groups and any observed 
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patterns will be interpreted extremely cautiously, owing to the smaller numbers and increased 
chance of Type I error. 
4.6 Quality of Life 
The quality of life questionnaires include disease specific (AVVQ) and generic (EQ5D & SF-
36) components. AVVQ will be recoded according to its manual3. The SF-36 will be scored 
using Health Outcome Scoring Software 4.0 for the physical health and mental health 
dimensions, and all eight scales, including physical functioning, role limitations due to physical 
health, role limitations due to emotional problems, energy/fatigue, emotional well-being, social 
functioning, pain, and general health. The index-based values (‘utilities’) will be calculated by 
the EQ-5D-5L Crosswalk Index Value Calculator downloaded from the EQ-5D official 
website.  
The QoL scores will be presented using line plots for each study arm to illustrate trends in 
AVVQ score, SF-36 and EQ-5D-5L over time (Figures 8-10). Depending on the distribution 
of the data, the means and 95% CI of means or medians and inter-quartile ranges at baseline, 
6-weeks, 6-months and 12-months after randomisation, will be reported (Table 9).  Analysis 
of variance will be used to explore changes in QoL over time and assess the difference between 
the two intervention groups.  
4.7 Markers for Clinical Success 
Clinical success will be assessed using the Venous Clinical Severity Score (VCSS), which is 
measured at baseline and 6 weeks post-randomisation. The change in clinical classification in 
the Clinical, Etiologic, Anatomic, Pathophysiological (CEAP) score at 6 weeks post-
randomization from baseline will be reported and the chi-square test will be used to compare 
between the two arms. Similarly, change in VCSS score will be compared between the two 
arms using the t-test (assuming change in VCSS is normally distributed) or appropriate non-
parametric test (if change in VCSS is not normally distributed).  
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Table 10 shows the proportions of patients with downgrade of clinical classification from C6 
to C5 at 6-weeks post-randomisation and VCSS score. The VCSS scores at 6 weeks post-
randomization and baseline will be summarised using boxplot for both arms (Figure 11).  
4.8 Safety Data 
The safety data, including adverse events (AEs) and serious adverse events (SAEs) will be 
provided in a tabular format for the two arms (Table 11 and Table 12). AEs will be summarised 
by description and outcome and SAEs will be summarised by SAE reason, frequency, severity, and 
relationship to treatment, outcome and expectedness.  
4.9 Derived Variables 
1. Deep vein reflux is defined as iliac, femoral, popliteal or crural deep vein reflux 
detected by Duplex scan. 
2. Deep vein obstruction is defined as iliac, femoral, popliteal or crural deep vein outflow 
obstruction detected by Duplex scan. 
3. Time to ulcer healing will be calculated as the difference between the final healing date 
and date of randomisation. Final healing date is collected in the InForm database and 
this variable is entered by trial manager after experts agree on the healing date. Patients 
will be censored at the time of last follow-up if they are dead, withdrawn or lost to 
follow-up before primary ulcer healing. The follow-up time is one year after 
randomisation and thus patients with unhealed primary ulcer at one year after 
randomisation will be also censored.   
4. One-year ulcer free time will be calculated as total follow-up time in days (i.e. one year 
or time to the last follow-up if patients are dead, withdrawn or lost to follow before one 
year) deducting the total duration of ulcers, including primary ulcer and recurrences.  
5. Ulcer chronicity will be calculated as the difference between the date of current ulcer 
appeared and the date of randomisation.  
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5. Sensitivity analysis 
As a sensitivity analysis, we will perform a per-protocol analysis by excluding patients with 
protocol violations. This sensitivity analysis will cover all primary and secondary outcomes. 
As the per-protocol analysis leads to the optimal effect of EVRA and could bring attrition bias, 
we will interpret the results of pre-protocol analysis with extreme caution. The surgeon data is 
collected separately and not included in the InForm database. If the surgeon data can be merged 
into the main database and, we will carry out another sensitivity analysis by including surgeon 
as a random effect in the Cox regression analysis for primary outcome.   
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Tables 
Table 1 Baseline characteristics between the EVRA and standard treatment group* 
 EVRA Standard 
 N= N= 
Age   
Height   
Weight   
BMI   
Gender   
Male   
Female   
Smoking   
Never   
Former   
Current   
Ethnicity   
White   
Mixed   
Asian   
Black   
Chinese   
Other   
EQ-5D   
Mobility   
Self-care   
Usual activities   
Pain/discomfort   
Anxiety/depression   
Health state score   
SF-36   
Physical function   
Role-Physical   
Body pain   
General Health   
Vitality   
Social Functioning   
Role-Emotional   
Mental Health   
Total AVVQ    
* Data presented as frequency (percentage) for categorical variables and mean (SD) for continuous 
variables 
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Table 2 Summary of medical history & concurrent medication* 
 EVRA Standard 
 N= N= 
Previous pregnancy†   
Yes   
History of DVT in 
pregnancy (yes) 
  
No   
Hormone therapy†   
None   
Previous HRT   
Current HRT   
Previous OC   
Current OC   
Previous Rheumatoid 
disease (yes) 
  
Previous DVT   
Current antiplatelet therapy   
None   
Aspirin   
Clopidogrel   
Other   
Current anticoagulation 
therapy 
  
None   
Warfarin   
New oral anticoagulants   
Other   
Current Steroids   
Yes   
No   
Current Trental 
(pentoxifylline) 
  
Yes   
No   
Diabetes   
Yes   
No   
* Data presented as frequency (percentage) for categorical variables 
† Female only  
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Table 3 Summary of ulcer history* 
 EVRA Standard 
 N= N= 
Previous ulcer (yes)   
Ulcer dressing   
NA   
Inadine   
Other   
Baseline Compression   
None   
KTwo   
Three-layer bandage   
Four-layer bandage   
European short stretch   
Stocking   
Other   
Time of wearing   
Day & night   
Day only   
* Data presented as frequency (percentage) for categorical variables 
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Table 4 Characteristics of current ulcer* 
 EVRA Standard 
 N= N= 
Time since ulcer diagnosis (months)   
Trial ulcer leg   
Right   
Left   
Ulcer location   
Lateral   
Medial   
Circumferential   
Ulcer size (cm2)   
Duplex Scan: Deep Vein   
Normal   
Abnormal†   
Reflux   
Outflow obstruction   
CEAP Score   
Clinical signs – grade   
C5   
C6   
Clinical signs – presentation   
Asymptomatic   
Symptomatic   
Etiologic classification   
Primary   
Secondary   
Deep   
No venous cause   
Anatomic distribution   
Superficial   
Perforator   
Deep   
Pathophysiologic dysfunction   
Reflux   
Obstruction   
Both   
No venous cause   
VCSS Score   
Palpable pedal pulses   
Yes   
No   
* Data presented as frequency (percentage) for categorical variables and median (range) for 
continuous variables 
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†A patient can have both deep vein reflux and obstruction 
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Table 5 Treatment summary 
 EVRA Standard 
N= N= 
Endothermal only   
Foam only   
Mechanochemical ablation (MOCA) only   
Endothermal and Foam   
MOCA and Foam   
* Data presented as frequency (percentage) 
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Table 6 Time to ulcer healing in patients with chronic venous ulceration (Cox regression 
model) 
 Univariate model* Multivariate model† 
HR (95% CI) P value HR (95% CI) P value 
Treatment     
Standard arm      
EVRA     
Age (yrs)     
Ulcer chronicity (mths)     
Ulcer size     
1st Quartile     
2nd Quartile     
3rd Quartile     
4th Quartile     
* Adjusted by centre (centre included in the model as a random effect) 
† Adjusted by centre, age, ulcer size and chronicity (centre included in the model as random effect and 
age, ulcer size and chronicity as fixed effects).  
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Table 7 Summary of 12-week and 24-week ulcer healing rate and ulcer free time* 
 EVRA Standard 
N= N= 
12-week ulcer healing rate   
24-week ulcer healing rate   
No. of patients with recurrent ulcer   
Ulcer free time   
* Data presented as frequency (percentage) for categorical variables and median (range) for 
continuous variables 
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Table 8 Multiple linear regression (ordinal regression)  for ulcer free time (days) to 1 year in 
patients with chronic venous ulceration  
 Univariate model* Multivariate model† 
Coefficient 
(95% CI) 
P value 
Coefficient 
(95% CI) 
P value 
Treatment     
Standard arm      
EVRA     
Age (yrs)     
Ulcer chronicity (mths)     
Ulcer size     
1st Quartile     
2nd Quartile     
3rd Quartile     
4th Quartile     
* Adjusted by centre (centre included in the model as a random effect) 
† Adjusted by centre, age, ulcer size and chronicity (centre included in the model as random effect and 
age, ulcer size and chronicity as fixed effects).  
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Table 9 Summary of quality of life (AVVQ, EQ-5D, SF36) at baseline, 6 weeks, 6 months 
and 12 months after randomisation 
  EVRA Standard 
 N Mean (SD) Mean (SD) 
AVVQ     
Baseline    
6 weeks    
6 months    
12 months    
EQ-5D health score    
Baseline    
6 weeks    
6 months    
12 months    
EQ-5D index value    
Baseline    
6 weeks    
6 months    
12 months    
SF-36 physical health    
Baseline    
6 weeks    
6 months    
12 months    
SF-36 mental health    
Baseline    
6 weeks    
6 months    
12 months    
* Data presented as mean (SD) or median (IQR), as appropriate   
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Table 10 Summary of clinical success at 6 weeks after randomisation 
 EVRA Standard 
 N= N= 
VCSS total score   
Yes   
No   
* Data presented as frequency (percentage) for categorical variables   
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Table 11 Summary of adverse events 
 EVRA Standard 
 N= N= 
No. surgical procedures   
Total number of AEs    
Description of AE   
Systemic   
Local   
Outcome   
Recovered   
Not yet recovered   
Death   
Unknown   
Missing   
* Data presented as frequency (percentage) for categorical variables   
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Table 12 Summary of serious adverse events 
 EVRA Standard 
 N= N= 
No. surgical procedures   
Total number of SAEs    
Serious reason   
Death   
Life threatening   
Persistently disabling   
Hospitalisation required   
Congenital abnormality   
Other   
Frequency   
Single Episode   
Intermittent   
Frequent   
Continuous   
Unknown   
Severity   
Mild   
Moderate   
Severe   
Life threatening or 
disabling 
  
Relation to procedure   
Not related   
Unlikely   
Possible   
Probable   
Definite   
Outcome   
Recovered   
Not yet recovered   
Death   
Unknown   
Expectedness   
Expected   
Unexpected   
* Data presented as frequency (percentage) for categorical variables  
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Figures 
Figure 2 CONSORT diagram of the study population 
Figure 3 Kaplan-Meier curve showing ulcer healing time in the EVRA and standard 
(delayed) arm  
Figure 4 Forest plot showing the treatment effect on time to healing by pre-defined 
sub-groups 
Figure 5 Forest plot showing the treatment effect on time to healing by different 
treatments 
Figure 6 Forest plot showing the treatment effect on ulcer free time by pre-defined sub-
groups 
Figure 7 Forest plot showing the treatment effect on ulcer free time by different 
treatments 
Figure 8 Time trend of EQ5D: a) Health Score; b) Index Value in the two arms 
Figure 9 Time trend of SF-36 in the two arms 
Figure 10 Time trend of AVVQ in the two arms  
Figure 11 Summary of clinical success: change in VCSS between baseline and 6 weeks 
after randomisation  
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Statistical analysis plan (SAP) – Summary of changes 
Version Date Reviewers Draft or Signed List of changes 
1.0 15/10/2014 Senior 
statistician 
Draft        N/A draft only 
2.0 08/04/2016 Internal study 
Team, TSC 
Signed by senior 
statistician and 
trial statistician 
       First effective version 
1. To update the sample size correction; 
2. To remove the adjustment of surgeon as a random effect in  all regression 
analysis as the data is not collected; 
3. To clarify the definition of ulcer-free time to 1 year and the analysis plan for 
ulcer free time; 
4. To clarify the analysis plan for 24-week healing rate; 
5. To clarify how to derive time to ulcer healing for censored patients; 
6. To add per-protocol analysis. 
3.0 02/06/2016 Internal study 
Team 
Signed by CI and 
trial statistician 
1. To update the protocol version number to 4.0 as the new protocol was 
approved.  
4.0 26/10/2017 Internal study 
Team, TSC 
Signed by CI, 
senior statistician, 
trial statistician, 
and TSC chair 
1. To include TSC chair’s signature as a results of trial unit SOP update; 
2. To update the protocol version number to 5.0 as the new protocol was 
approved; 
3. To change the primary outcome analysis from study centre-stratified log-rank 
test to univariate Cox regression adjusting for study centre as random effect, so 
that the treatment effect can be quantified; 
4. The clarify the population for analysis; 
5. To include the summary of interventional treatment; 
6. To define the subgroup analysis; 
7. To clarify the methods to check cox regression model assumption; 
8. To clarify the analysis method for QoL data. 
 
Summary of SAP deviations: 
1. The sensitivity analysis of ulcer free time to 1-year in all the patients was not performed as this would be biased (see pages 8-9 of SAP V4.0) 
2. The analysis method for quality of life data was amended from a variable to mix-model analysis as a mix-model is more appropriate for time-series 
data.   
